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Abstract
Population-based cancer studies can contribute to a better understanding of cancer patient survival.
The general aim of this thesis was to develop and apply statistical methods for population-based cancer
studies to ensure understanding in this area.
In any analysis setting, it is important that the statistical methods are appropriate. Since non-
proportional hazards are common in population-based data where follow-up is long, Study I assessed
the ability of flexible parametric models (FPMs) in capturing time-dependent effects in a simulation
setting. This study also attempted to determine whether the Akaike Information Criterion (AIC) or the
Bayesian Information Criterion (BIC) were more appropriate in selecting a good-fitting model. Results
indicated that bias was small for estimated survival proportions, hazard rates and log hazard ratios
when degrees of freedom were selected using guidance from the AIC or BIC. Neither the AIC nor the
BIC constantly outperformed the other. We concluded that FPMs accurately capture time-dependent
effects but that users should perform appropriate sensitivity analyses.
There have been large changes in treatments for chronic myeloid leukaemia (CML) patients over
time; most notably is the introduction of imatinib mesylate, a targeted therapy, in 2001. Studies have
shown that relative survival of CML patients greatly improved after the introduction of this treatment.
Since CML is a chronic disease, quantifying survival in terms of life expectancy is highly relevant. In
Study II we aimed to quantify life expectancy improvements using the loss in expectation of life measure.
Results indicated that patients diagnosed in 2013 would be expected to lose less than three of their
remaining life years due to their CML diagnosis. We concluded that the life expectancy among CML
patients is approaching that seen in the general population and improvements over time are largely due
to imatinib mesylate and allogeneic stem cell transplantation.
Population-based mortality rates are often used as a proxy for the mortality rate a diseased popula-
tion would have experienced had they been disease-free; these are used in relative survival analysis and
when calculating standardised mortality ratios. Population-based mortality rates are commonly available
by age, calendar year and sex which might limit analyses to these factors. In Study III we described
methodology to adjust population mortality rates by additional variables, such as socioeconomic status,
that are available in a control population. We presented both Poisson and flexible parametric methods
and found that both methods estimate similar mortality rates by socioeconomic status. Adjusting for the
additional uncertainty associated with the methodology presented made little difference to five-year
relative survival of breast cancer patients.
Socioeconomic status is known to affect the survival of breast cancer patients. Stage at diagnosis of
breast cancer is also known to have a strong effect on survival and the distribution of stage at diagnosis
often differs by socioeconomic status. In Study IV we aimed to quantify survival differences between
education groups as a proxy for socioeconomic status. We estimated that 572 life years could be saved,
and 25 deaths could be postponed five years beyond diagnosis, if differences between education group
in the breast cancer stage-distribution could be removed in three regions of Sweden. If differences
between education groups in stage-specific breast cancer survival could be removed, we estimated that
692 life years could be saved, and 27 deaths postponed five years beyond diagnosis.
In conclusion, this thesis reassures users of FPMs of their performance under non-proportional
hazards. Secondly, methodology is described to further adjust expected mortality rates which could aid
researchers in estimating survival measures by additional, non-standard variables. Finally, this thesis
provides a greater understanding of the probable prognosis and the burden of CML and breast cancer
diagnoses via the loss in expectation of life and other similar measures.
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1. Introduction
It is well known that most of us will be affected, either directly or indirectly, by some form(s) of
cancer in our lifetime. In Sweden, and globally, the incidence of cancer is (generally) increasing
[1]. Whilst screening and other improvements in the detection of cancer can contribute to this,
the main reason for the increase in incidence is population aging. Malignant tumours remain
the largest cause of death in Sweden, second only to cardiovascular diseases [2].
For these reasons, it is essential that research continues to focus on understanding the causes,
treatments and potential cures for cancer. At the same time, it is important to determine the
effectiveness of the healthcare system in terms of cancer care, and this is what population-based
cancer studies aim to do. Such studies can, for example, evaluate temporal trends in cancer
patient survival and evaluate the burden of cancer on a population level to provide guidance
for healthcare policies and plans for cancer control whilst providing insight into the probable
prognosis of patients [3, 4].
Population-based cancer studies use population-based data to quantify survival and other
measures in cancer patients from a certain geographical area. Many population-based cancer
studies are based on data from cancer registries that collect information on diagnoses of cancer
within whole nations. Three important measures are frequently reported from such studies:
incidence rates, survival proportions and mortality rates [5, 6]. Incidence rates measure the
number of new cases of a disease within a population during a specific time period. To un-
derstand the probability of survival at a given time point within a group of patients, survival
proportions are estimated, whilst mortality rates are death rates calculated for the whole popu-
lation. Each of these measures describe different elements of the effect of cancer in a population
and together they provide an evaluation of the impact and control of cancer in a population.
In this thesis, focus is on the cancer patients and quantifying their survival.
Using data from Swedish registries, we quantify the impact cancer diagnoses have on the
population and estimate the likely outlook for patients who are diagnosed with cancer using
sophisticated statistical methods. Statistical methods are a vital element in all research areas
including population-based cancer studies; without correct statistical methods and inference,
results will likely be false and misleading. The work in this thesis focuses on assessing, ex-
tending and applying sophisticated statistical models that quantify the impact cancer has on a
population.
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2. Aims of this thesis
This doctoral project is centered around statistical methods involved in the analysis of population-
based cancer studies using flexible parametric survival models. Particular focus is on applica-
tions of the loss in expectation of life measure to encourage understanding of cancer-patient
survival.
More specifically, the aims were:
• To assess the ability of restricted cubic splines in flexible parametric models in capturing
time-dependent effects and determine whether one of the standard information criterion
used for the selection of degrees of freedom should be preferred (Study I).
• To estimate the loss in expectation of life in Swedish chronic myeloid leukaemia patients
(Study II).
• To investigate and compare methods which extend population-based expected mortality
rates to adjust for variables other than age, sex and year by using information available
from a control population (Study III).
• To apply methods developed in Study III to be able to estimate the loss in expectation of
life by highest educational achievement in Swedish breast cancer patients (Study IV).
• To quantify the total life years lost and postponable deaths of Swedish breast cancer
patients if differences between education groups could be removed in terms of differences
in stage-distribution and stage-specific relative survival (Study IV).
2
3. Background
3.1 Cancer
3.1.1 What is cancer?
Statistical methods are the focus of this thesis, but some basic understanding of cancer is
necessary. Simply stated, cancer is a disease which is defined by abnormal cell growth. Most
cells in the human body grow, divide and eventually die. In regular cells, the division process is
organised and any mutations are removed via programmed cell death. In contrast, cancer cells
do not follow the regular rules of cell division and cell death. The process is characterised by
uncontrolled growth and replication, and the evasion of programmed cell death [7]. It begins
with a mutation or gene alteration which affects cell homeostasis [8]. Malignant tumours invade
surrounding tissue and have the capacity to spread to distant organs, also called metastases
[9]. When this happens, the cancer is said to have metastasised. The term cancer encapsulates
many different related diseases. So-called solid tumours are usually named based on the tissue
or organ where the cancer originated.
Risk factors for cancer differ depending on the specific disease. Generally risk factors include
age, alcohol intake, diet, obesity, radiation exposure and tobacco usage [10]. Such risk factors
can also affect the prognosis of patients diagnosed with cancer. An additional important prog-
nostic factor is stage at diagnosis. Stage refers to the size and location of the primary tumour,
spread to the regional lymph nodes, and formation of distant metastases. Early stage refers to
localised (and usually curable) disease, whereas advanced stage refers to distant metastatic
disease.
3.1.2 Cancer in this thesis
The statistical methods in this thesis are applicable to most cancers provided certain assump-
tions hold. Two specific cancers that are analysed in this thesis are chronic myeloid leukaemia
(Study II) and female breast cancer (Studies III and IV).
Chronic myeloid leukaemia
Chronic myeloid leukaemia (CML) is a haematological neoplasm which is characterised by
the presence of the t9;22 translocation (the Philadelphia chromosome). CML is normally a
slow growing leukaemia which can progress into a more advanced phase (either accelerated or
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blastic). The majority of patients diagnosed with CML are diagnosed in the chronic phase and
these patients currently tend to take treatment for life where the goal of such treatment is to
prevent progression to a more advanced phase. The only cure for CML is to undergo allogeneic
stem cell transplantation.
Treatment of CML has changed enormously over the years, which has resulted in a dramatic
improvement in the survival of CML patients. Prior to the 1990s, CML patients experienced a
median survival time of 3.2 years [11]. Allogeneic stem cell transplantation was the preferred
treatment for those patients healthy enough to undergo it during the 1990s, and was shown
to increase median survival time to 4.7 years [12]. A molecularly targeted anti-cancer agent
called imatinib mesylate (IM), commonly known as Gleevec or Glivec, was introduced in 2001
in Sweden. This was after randomised controlled trials showed survival gains in comparison to
other standard treatments [13]. Since then, several targeted therapies similar to IM have been
introduced to treat patients who are resistant or intolerant to IM. Recently, results from clinical
trials have suggested that IM can be discontinued for a large proportion of CML patients who
experienced a very good response to treatment [14].
Risk factors for CML are largely unknown. However, exposure to radiation and increasing
age have been shown to increase the risk of being diagnosed with CML. In Sweden, the median
age at diagnosis is 60 years of age [15] and the incidence of CML is estimated to be 0.9 per
100,000 person-years; the incidence has largely remained constant over calendar year. Survival
gains over calendar year have driven a dramatic increase in the prevalence of CML in Sweden,
and prevalence is predicted to continue to increase over time [16]. Five-year relative survival
is estimated to be 80% for Swedish patients diagnosed after the introduction of IM [11]. This
estimate varies between different ages with better relative survival seen in younger patients.
Breast cancer
Breast cancer is the most common female cancer in Sweden. It represented 30% of all female
cancers diagnosed in Sweden between 2011 and 2014. In 2014 there were 9,730 diagnoses
of female breast cancer in Sweden [17]. The number of breast cancer diagnoses has been
increasing over time whilst mortality has been decreasing [18, 19]. Risk factors for the incidence
of breast cancer include family history of breast cancer, increasing age and breast density, among
other factors [20].
Survival of breast cancer is generally high. The one-year age-standardised relative survival
between 2011 and 2015 was estimated to be 0.98 (95% CI: 0.97-0.98) and at five years this was
estimated as being 0.89 (95% CI: 0.89-0.90) [19]. There are many factors which affect survival
of breast cancer patients including age, patient and tumour characteristics, and treatment.
Mammographic screening was introduced in Sweden throughout the 1980s and 1990s and has
been shown to increase the survival of breast cancer patients [21]. The Swedish National Board
of Health and Welfare recommends that women aged 40-74 years be invited to mammographic
screening every 18 to 24 months. Stage at diagnosis and socioeconomic status (SES) have been
shown to affect survival of breast cancer patients. The effects of these factors are explored
4
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in Study IV. There is evidence that patients diagnosed at a younger age often have a more
aggressive disease and thus have a poorer prognosis [22] and it is known that advanced stage
at diagnosis is also related to poorer prognosis. Additionally, there is evidence that survival
differences between SES groups are partly due to differences in stage at diagnosis [23, 24, 25].
3.2 Survival analysis
3.2.1 A short overview of key concepts and measures in survival analysis
This thesis focuses on the survival of cancer patients and in order to describe this methodology,
a short overview into the area of survival analysis is useful.
Survival analysis refers to statistical methods which analyse time-to-event data, where
observations are followed over time until an event (or events) of interest. This thesis considers
only one event of interest. The main components of this type of data are time, t i, from a
specified origin time, and an indicator for whether observation i experienced the event, di , or
not. One of the elements of survival analysis that separates it from other statistical methods
is censoring. Censoring occurs when the event status for an observation is not known [26].
There are different types of censoring, but in this thesis only right censoring is considered.
Right censoring occurs when up until a certain time point no event has been observed. After
this point we can no longer follow the observation; we know that sometime in the future the
event could be observed but are no longer able to record it. This is the most common form of
censoring in population-based cancer studies. It is important to note here that the assumption
of non-informative censoring is made throughout this thesis, i.e., that censoring is independent
of the event of interest. In addition, all survival data in this thesis are considered independent;
when analysing correlated survival data other methods are required [27].
Three measures of importance which describe the relationship between the event time T
and the event of interest are the survival function, the hazard function, and the cumulative
hazard function. The survival function S(t) can be defined as follows and is the probability the
event of interest occurs after a certain time-point t,
S(t) = Pr(T > t).
The hazard function h(t) defined below represents the instantaneous rate at time t of experi-
encing the event of interest and is presented per-person time
h(t) = lim
δ→0
Pr(t ≤ T ≤ t +δ|T ≥ t)
δ
.
It is common to multiply the hazard rate by 1,000 or 100,000 and subsequently present the
rates per 1,000 or 100,000 person-years. The cumulative hazard H(t) is highly useful when it
comes to modelling survival data, as described in section 5.1. The cumulative hazard function
5
3. Background
is defined as
H(t) =
∫ t
0
h(u)du.
Whilst the survival function is monotonic-decreasing and the cumulative hazard function
is monotonic-increasing, the hazard function can be any non-negative function; see Figure 3.1
for an illustration of these measures. These three measures are all related to one another; the
most important relationships are described below. Note that in this thesis mortality rate and
hazard rate are used interchangeably to refer to the instantaneous rate of death within the
cancer patient population.
h(t) = − d
d t
log S(t) (3.1)
S(t) = exp

−
∫ t
0
h(u)du

= exp[−H(t)] (3.2)
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Figure 3.1: Examples of three important measures commonly used in survival analyses as functions
of time. (a) shows the survival proportion, (b) the hazard function, and (c) the cumulative hazard
function.
3.2.2 The Cox proportional hazards model
The Cox model [28] is the most common survival model used to date, and the second most
cited statistical paper [29]. The Cox proportional-hazards model is formulated as follows
h(t;x) = h0(t)exp(βx) (3.3)
where x represents covariates, β their estimated coefficients, and h0(t) represents the baseline
hazard function, i.e., the hazard when all covariates are zero or at their specified baseline levels.
In the Cox model, only the coefficients β are estimated, not the baseline hazard, thus hazard
ratios (HRs) are estimated, but no absolute effects are directly estimated.
In contrast to the Cox model where the baseline hazard function is not directly estimated,
we can make assumptions about the shape of the baseline function via parametric models; a
brief description of these is given in section 5.1. One parametric model which is commonly
used for the analysis of survival data is the Poisson model.
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3.2.3 Modelling hazard rates using the Poisson model
Poisson models can also be used to model time-to-event data (Study III). Poisson models are
commonly used for modelling count data but can also be used to model rates by introducing
an offset into the model. An offset is a variable included in a model where no coefficient is
estimated, i.e., the coefficient is forced to be equal to one. The log hazard rate can be modelled
using Poisson models by introducing an offset of the person-time at risk, y, and using the
relationship mortality h(t) = nd/y , where nd represents the number of deaths.
ln(nd) = f (t) + βx+ ln(y)
⇒ ln(nd/y) = f (t) + βx
⇒ ln[h(t)] = f (t) + βx (3.4)
Note that the effect of time must be included in the model via f (t). This is commonly
done by splitting the time at risk into intervals, thus the number at risk and person-time at risk
are also split into different time intervals. It is assumed that the hazard rate within each time
interval is constant; these models are also called piecewise constant hazard models for this
reason. It is also possible to subsequently smooth the piecewise constant hazards, for example
by using splines [30]. As described above in equation (3.4), these models assume proportional
hazards but this assumption can easily be relaxed by including interactions between variables
and a function of time. A description of the proportional hazards assumption comes next.
3.2.4 Proportional versus non-proportional hazards
The term proportional hazards refers to the modelling assumption that the ratio of two hazard
rates is constant over time, i.e., that the HR is constant over time. Allowing for non-proportional
hazards means that two hazard rates are allowed to vary differently over time and thus the HR
of these two rates can vary over time. Although it is often easier to interpret coefficients from
a proportional hazards model, it is in fact common to see non-proportional hazards especially
when follow-up is long (as is commonly the case for population-based studies).
In order to allow for non-proportional hazards, a model must include an interaction term
between time and the covariate which is intended to have a time-dependent effect. Note
that time-dependent effects or time-dependent coefficients are different from time-varying
covariates; the latter refers to the situation where covariate values change over time, not
necessarily their effects. A hazards model is described as having non-proportional hazards if
one or more of the coefficients are allowed to vary over time. It is possible to extend the Cox
model to incorporate non-proportional effects [31] although it is easier to estimate these effects
when making some assumption about the shape of the underlying hazard, as is the case in
parametric models.
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Figure 3.2: Proportional hazards versus non-proportional hazards. Purple lines are from a proportional
hazards model whilst blue lines are from a non-proportional hazards model. (a) shows hazard rates for
two levels of a covariate, solid and dashed lines represent the levels, and (b) shows the corresponding
HRs.
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The analyses and method development undertaken in this thesis were possible due to data
contained in several population-based registers in Sweden. These population-based registers
are used for many different purposes including incidence monitoring and assessment of quality
of care and are also utilised within various research areas. In Sweden, every individual who
is registered as a resident for at least a year is provided with a unique personal identification
number. This number is used in many aspects of society including all contact with the Swedish
healthcare system. The personal identification number is included in population registers and
allows many of these registers to be linked. The linkage of registers creates a rich tool for
research [32]. Note that data protection regulations require that the personal identification
number is not available for research purposes, instead a pseudo-identification number is used.
This thesis uses data from the Swedish Cancer Registry, the Breast Cancer Database Sweden
(BCBaSe, a data merge based on data from the Regional Breast Cancer Clinical Quality Registers
and other registers), and expected mortality data which are described in the following sections.
4.1 The Swedish Cancer Registry
The Swedish Cancer Registry (SCR) was established in 1958 and contains all individuals with
a permanent residency in Sweden who have had a diagnosis of cancer. Six regional cancer
centers were founded in the 1980s, where information on diagnoses of cancer are first sent
to be registered, checked and coded. The national register is then compiled at the Swedish
National Board of Health and Welfare (NBHW) who are responsible for the SCR [33]. The na-
tional register is updated once a year and approximately 50,000 malignant cases are recorded
annually. By law, healthcare providers must report a diagnosis of cancer. In fact, most individ-
uals diagnosed with cancer will be reported twice to the regional cancer centers; one report
commonly comes from the initial diagnosis by a clinician and the second from a pathologist.
Cancer diagnoses only recorded on death certificates are not recorded in the SCR. Information
in the SCR includes patient characteristics such as sex and age, and medical data including site
of tumour, date of diagnosis, and TNM stage (collected since 2004). Date of death and cause of
death is obtained through linkage to the Swedish Cause of Death Register. The completeness of
the register has been estimated to be above 96% [34]. Study II analyses Swedish CML patients
using information from the SCR.
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4.2 Breast Cancer Database Sweden (BCBaSe)
BCBaSe is a register merge based on information from three out of six Regional Breast Can-
cer Clinical Quality Registers (RQRBC). Since 1992, the six Swedish healthcare regions have
reported to the separate RQRBC. BCBaSe contains information from the Stockholm-Gotland,
Uppsala-Örebro, and North regions which together cover approximately 60% of the total popu-
lation. Such clinical registers record detailed and individual-specific diagnostic and treatment
information in the aim to evaluate and develop care for patients. Using data included in such
registers for research purposes is becoming increasingly common.
BCBaSe contains information on clinical data including patient and tumour characteristics,
clinical stage and treatment information from 1992 to 2012, alongside five controls per case
matched on birth year and county of residence. BCBaSe was created by linking data from the
RBCQR to data from the SCR, Cause of Death Register, and Total Population Register to confirm
vital status, and for selecting controls. The data was further linked with the following data
sources:
• The Longitudinal integration database for health insurance and labour market studies
(LISA). This database contains, among others, information on SES from censuses, highest
education achievement and disposable income for Swedish residents aged 16 years and
over.
• The MiDAS database from the Swedish Social Insurance Agency. Information on sickness
and other social benefits are available in BCBaSe from MiDAS.
• The National Patient Register. This register records all in-patient healthcare and specialist
outpatient healthcare. The data linked to BCBaSe from this register can be used for
quantifying comorbidities.
• The Multi-Generation Register. Information on relatives with breast cancer is obtained
using this register in combination with the SCR. The Multi-Generation Register links
individuals born in 1932 or later and who were registered in Sweden since 1961, to their
parents.
• The Prescribed Drug Register. This records all prescriptions given to individuals in Sweden
from 2005.
In Study III and IV, education information at the time of diagnosis from LISA is utlilised and
used as a measure of SES for breast cancer cases (both Study III and Study IV) and controls
(only Study III).
4.3 Expected mortality rates
In contrast to observed mortality rates among cancer patients, expected mortality rates are
mortality rates calculated for a whole population. These rates are often used as a proxy for the
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mortality diseased patients would have experienced had they been disease-free. Such rates are
contained in tables referred to as life tables, or population mortality files. Expected mortality
rates are commonly presented by age, sex and calendar year since these are often the only
factors affecting mortality that are available for the whole population. Alternatively, methods
can be implemented to additionally adjust these tables as illustrated in Study III of this thesis.
The expected mortality rates used in this thesis are taken from the Human Mortality Database
[35] which contains expected mortality rates for a number of countries including Sweden.
The databases are available to download from the Human Mortality Database (http://www.
mortality.org/) after becoming a registered user on their website. The Swedish expected
mortality rates contained in the Human Mortality Database are obtained from Statistics Sweden.
The use of expected mortality rates in population-based cancer survival analyses is described
further in section 5.2.2 of this thesis.
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5.1 Flexible parametric models
As described in the previous chapter, the most commonly implemented model when considering
survival data is the Cox model. The Cox model makes no assumption on the shape of the
baseline hazard function and is able to directly estimate relative effects, but not absolute effects.
Although relative effects, like HRs, are very interesting, absolute effects help provide a greater
understanding of the survival outlook. Alternatively to the Cox model, parametric models can
be fitted. Parametric models make assumptions on the shape of the baseline hazard meaning
they are able to directly estimate both relative and absolute effects. Flexible parametric models
(FPMs) offer a good alternative to standard parametric models, such as the Weibull model,
since they are able to capture simple and complex effects that such standard parametric models
may struggle to capture [36]. Furthermore, due to their modelling of the baseline function,
FPMs can be used to estimate many useful measures such as time-dependent HRs and hazard
differences.
Royston and Parmar first introduced FPMs in 2001 as a tool for various forms of survival
analysis [37]. These models have since been extended in a variety of settings including relative
survival [38], to estimate cure [39] and incorporating random effects [40]. This thesis focuses
on the use of FPMs in estimating relative survival and subsequently estimating the loss in
expectation of life. The key to the flexibility of these models is their use of restricted cubic
splines (RCSs). RCSs in FPMs model some transformation of the survival function. Here focus
is on RCSs modelling the log cumulative hazard function and the log hazard function, although
they can also model on other scales. RCSs are piecewise cubic polynomials joined together
at points called knots [41]. The first and second derivatives at these join points are forced to
be continuous to ensure the resulting function is smooth. The RCSs are additionally forced to
be linear before the first, and after the last knot to ensure that data in the extremes do not
affect the function excessively. Users select the number of knots, which dictate the degrees of
freedom (the number of knots minus one), and determine how complex the resulting RCS is.
An RCS function, s(α;γ0), with α= t or ln(t) and knots k1, ..., kK is defined as
s(α;γ0) = γ00 +
K−1∑
l=1
γ0l vl(α),
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where the lth basis function vl(α) is defined as
vl(α) =
α, for l = 1(α− kl)3+ −λl(α− k1)3+ − (1−λl)(α− kK)3+, for l = 2, ..., K − 1, (5.1)
and where k1 and kK are the boundary knots,
λl =
kK − kl
kK − k1 and
w+ =
¨
w if w> 0
0 if w≤ 0.
Splines are often orthogonalised to avoid any problems that can arise due to them being
correlated. Figure 5.1 shows an example of a mortality rate modelled using an RCS with four
degrees of freedom for malignant melanoma where the knot positions are illustrated with
vertical lines. The scattered points show mortality rates estimated using the number of events
and person time at risk in monthly intervals.
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Figure 5.1: An illustration of an RCS used to model the log mortality rate for malignant melanoma
patients. Points illustrate monthly mortality rates. The solid line represents the smooth RCS function
with knots placed at the vertical dashed lines.
It is also important to note that similarly to the way RCSs are used in FPMs to model
the baseline function, they can also be used to model continuous covariate effects. Instead
of categorising continuous variables or making the assumption that the effect is, for example,
linear, one can instead assume that the effect of a continuous covariate is captured by an RCS
function with specified degrees of freedom. In all studies in this thesis, the effect of continuous
covariates are modelled in this way.
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5.1.1 Modelling on the log cumulative hazard scale
It is common for FPMs to be implemented on the log cumulative hazard scale. FPMs assuming
proportional hazards on the log cumulative hazard, ln[H(t;x)], can be written as
ln[H(t;x)] = s(α;γ0) + xβ , (5.2)
where t represents time, x are covariates, and s(α;γ0) is an RCS function which here represents
the baseline log cumulative hazard function. Non-proportionality is introduced into FPMs by
including interactions between the covariates that are to have time-dependent effects, and
time. It is common to include RCSs as a function of log time, but the untransformed time scale
can be used and is useful when using age as the underlying timescale.
Time-dependent effects, or non-proportionality of J covariates, can be modelled by extend-
ing equation (5.2) in the following way
ln[H(t;x)] = s(α;γ0) + xβ +
J∑
j=1
s(α;γj)xj. (5.3)
It has been shown that HRs estimated from FPMs are similar to those estimated from
Cox models [36, 42]. Furthermore, Rutherford et al. showed that FPMs accurately capture
both simple and complex hazard functions provided enough knots are specified for the spline
function [43] under proportional hazards. In Study I of this thesis, we extended this work to
assess FPMs under non-proportional hazards and similarly concluded that RCSs are able to
capture a variety of hazard functions with small/minimal bias given an appropriate number of
knots are specified.
Maximum likelihood estimation is used to fit FPMs where the log-likelihood contribution
of the ith individual is
ln li = di ln[h(t i)] + ln[S(t i)]
= di ln[h(t i)]−H(t i). (5.4)
Equation (5.4) is calculated using the relationship between the hazard function and the cu-
mulative hazard function described in equation (3.2). This means that on the log cumulative
hazard scale, the components of the likelihood function for fitting FPMs can all be analytically
obtained. Equation (5.4) can be extended to include delayed entry (this is the case in Study IV
where a period approach is used, see section 6.4.2) by adding the cumulative hazard at entry
time:
ln li = di ln[h(t i)]−H(t i) + H(t0i) (5.5)
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5.1.2 Modelling on the log hazard scale
One of the reasons for modelling on the log cumulative hazard scale rather than the log hazard
scale is that numerical integration is required to model on the log hazard scale which can be
computationally intensive. Moreover, the coefficients estimated from the cumulative hazards
model can often be interpreted as log HRs; see appendix A.1 for an illustration of this. On the
other hand, there are good reasons to accept the inconvenience involved in numerical integra-
tion and model on the log hazard scale. One such reason is that we can avoid problems that
we encounter when modelling multiple time-dependent effects on the log cumulative hazard
scale. The HRs of variables with time-dependent effects are dependent on other covariates with
time-dependent effects when modelling multiple time-dependent effects on the log cumulative
hazard scale; see appendix A.2 for an example of this issue.
An FPM on the log hazard scale, ln[h(t;x)] with J time-dependent effects can be defined
as follows:
ln[h(t;x)] = s(α;γ0) + xβ +
J∑
j=1
s(α,γj)xj. (5.6)
Modelling FPMs on the log hazard scale is easy to implement in Stata [44] using the strcs
command; this is presented in a related publication [45] and described in Study I and Study
III. The log-likelihood used when fitting FPMs on the log hazard scale is presented in equation
(5.4) and can be rewritten in the following way:
ln li = di ln[h(t i)]−
∫ t i
t0i
h(u)du. (5.7)
The integral included in equation (5.7) cannot be calculated analytically due to the inclusion
of RCSs in the hazard function. Thus, numerical integration methods must be implemented to
calculate the log likelihood. Gaussian quadrature is a method of numerical integration that is
implemented when modelling FPMs on the log hazard scale. Gaussian quadrature converts an
integral into a summation in the following way:∫ 1
−1
g(x)d x ≈
M∑
m=1
wm g(xm) (5.8)
The summation is performed over pre-defined points called nodes, denoted m here, and weighted
by wm. In our application of Gaussian quadrature we calculate the integral between time t and
the entry time t0. Equation (5.8) can be altered to integrate between these time points in the
following way [45, 46]:∫ t
t0
g(x)d x ≈ t − t0
2
M∑
m=1
wm g
 t − t0
2
xm +
t0 + t
2

(5.9)
Note that Gauss-Legendre quadrature is used in the Stata command strcs to numerically
integrate the hazard function for each individual to get the cumulative hazard function needed
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to maximise the likelihood function. Gauss-Legendre quadrature sets the weights wm = 1.
5.1.3 Model selection
It is important to remember that there may be several good models which fit to analysis data.
Still, model selection is highly important since we wish to draw accurate conclusions from the
statistical method we choose. Selecting a reasonable model usually consists of 1) considering
which type of model is appropriate for the data on hand, e.g., a Cox or FPM for survival data,
and 2) selecting appropriate variables to include in the model which explain the variation in
the outcome, e.g., categorical age, or an RCS for age, when modelling time-to-death.
An important aspect of model selection for FPMs is the selection of the degrees of freedom. In
this context, the degrees of freedom can both refer to the complexity of the RCS that models the
baseline function and separately the complexity of the RCS used to model the time-dependent
effects. Information criterion are highly useful when selecting degrees of freedom for FPMs.
The Akaike Information Criterion (AIC) [47] and the Bayesian Information Criterion (BIC)
[48] are commonly used criteria that are calculated to aid FPM selection [36, 42]. Letting the
likelihood be denoted L, p be the number of parameters within a model, and n be the number
of observations, the AIC and the BIC are defined as follows:
AIC = −2 ln L + 2p BIC = −2 ln L + n ln(p).
Note that within the time-to-event framework, n is often taken to be the number of events
rather than the number of observations [49]. The models corresponding to the lowest AIC and
BIC are the best-fitting models according to each criteria. It is important to be aware that the
best-fitting model suggested by the AIC may not the same as the best-fitting model suggested
by the BIC. Study I concluded that the AIC and BIC should be used to guide FPM selection.
5.2 Net survival
Net survival is defined as the survival probability of cancer patients when removing death due
to other causes, i.e., survival if cancer patients could only die of their particular cancer. This may
at first seem a strange measure to use since this is not what happens in reality. However, the
advantage of this measure is that it is independent of differences in the non-cancer mortality,
thus fair comparisons can be made between different populations and different time periods
where the mortality rate due to causes other than cancer may vary. For example, consider a
comparison between the survival of a certain cancer in two equal-sized populations. Population
A are prone to have comorbidities and subsequently a high mortality rate due to causes other
than cancer. In comparison to population A, population B has a lower mortality rate due to
other causes. Suppose the mortality due to cancer in each of the populations is the same at all
points in time. The all-cause survival in the two populations would indicate that population
A has a worse survival than population B purely due to their increased risk of dying from
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causes other than cancer. For this reason, it is interesting to estimate net survival, where we
can remove mortality due to other causes and concentrate on cancer-specific survival.
There are two frameworks in which net survival can be estimated: 1) a cancer-specific
framework, or 2) a relative survival framework. In this thesis we rely on estimating net sur-
vival via relative survival. A summary of terms and measures are given in table 5.1 to aid
understanding and clarify the concepts presented in this chapter.
Survival measure Details Mortality measure
Survival of cancer patients when
Net survival, NS(t)
removing other-cause mortality.
Net mortality
Ratio of the all-cause survival
Relative survival, R(t) and the expected survival. Excess mortality, λ(t)
Estimates net survival∗
Survival of cancer patients where
patients are followed until death
due to cancer, other deaths
are censored.
Cause-specific survival
Estimates net survival∗
Cause-specific mortality
Survival of cancer patients
where patients are followed until
death due to any cause.
All-cause survival, S(t)
Can also be called observed survival.
All-cause mortality, h(t)
Survival expected if the cancer
patients had been cancer-free.
Expected survival, S∗(t) Population survival is used as a Expected mortality, h∗(t)
proxy for this using population
life tables.
∗Under certain assumptions
Table 5.1: Summary of measures used in Chapter 5.
5.2.1 Relative survival framework
Within the relative survival framework there are several estimators of net survival, one of which
is the relative survival estimator itself [50]. Relative survival, R(t), is defined as the all-cause
survival of the cancer patients, divided by the all-cause survival expected had these patients
been cancer-free [51].
R(t) =
S(t)
S∗(t) (5.10)
The hazard analogue of relative survival is called the excess mortality. When the excess
mortality equals zero, the survival in the cancer patient cohort and the expected survival are
equal. Excess mortality, λ(t), is the all-cause mortality observed in the cohort of cancer patients,
h(t), minus the expected mortality had the cancer patients been cancer-free, h∗(t). It aims to
capture mortality due to cancer.
λ(t) = h(t)− h∗(t) (5.11)
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Relative survival is a popular measure for estimating net survival since it does not require
accurate cause of death information. Cause of death information can be unreliable [52], and
even if reliable, it may not be clear if cancer is the primary cause of death. For example, cause of
death data often exclude treatment-related deaths. In theory, such deaths should be recorded
as due to cancer since these patients would not have died due to the treatment without the
diagnosis of cancer. However, in practice, it is impossible to know whether a non-cancer death
was related to cancer treatment or not.
Relative survival is often reported as an average measure for a particular population, com-
monly at a specific number of years post-diagnosis. This average measure is usually an internally
age-standardised estimate of relative survival, i.e., a weighted average according to the age
distribution found in the population under analysis. In contrast, external age-standardisaton is
important when comparing populations whose age distributions may differ. When externally
age-standardising, an alternative age distribution is forced on the population under study, for
example, the age distributions described in the International Cancer Survival Standards [53].
In reality we expect the relative survival and excess mortality to vary by individual i. As a
result, when we model we estimate relative survival on an individual level based on disease
and patient characteristics. Individual level estimates are predicted in studies II, III and IV.
The relative survival estimator can be calculated from both a life table approach, or using
a modelling approach. It is important to mention that there are several approaches in the life
table framework, the Ederer II approach is the most commonly used method for estimating
expected survival [54]. It has been shown that these estimators do not perfectly estimate net
survival [55]. The correct estimate of net survival is:
NS(t) =
1
n
n∑
i=1
Si(t)
S∗i (t)
=
1
n
n∑
i=1
Ri(t). (5.12)
However, the traditional life table approaches calculate this as the ratio of the average
all-cause survival and the average expected survival:
R(t) =
1
n
∑n
i=1 Si(t)
1
n
∑n
i=1 S
∗
i (t)
. (5.13)
Bias has been shown to be minimal when age-standardising relative survival estimates
calculated as in equation (5.13), and that there may be some added benefits in terms of precision
for longer term estimates of relative survival [56, 57]. In comparison to the traditional methods,
Pohar Perme et al. proposed an unbiased estimator of marginal net survival. This Pohar Perme
method directly estimates internally age-standardised net survival without stratifying by age,
by accounting for informative censoring. Note that when we model relative survival we directly
estimate Ri(t) for each individual i, and can standardise as shown in equation (5.12).
In order for the marginal relative survival measure to estimate marginal net survival one
must be willing to make two assumptions. Firstly, that the cancer population and the general
population are independent conditional on the matching variables, most commonly age, sex
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and calendar year, and variables included in the analysis. Secondly, that the mortality in the
general population, or the expected mortality, represents the mortality the cancer patients
would have experienced had they been cancer-free.
There are situations when estimating net survival is not of interest, rather we are interested
in estimating survival in the real world where patients can die of other causes as well as their
cancer. Competing risks methods that estimate these crude probabilities are not discussed
in this thesis. Instead we focus on a measure called the loss in expectation of life (LEL), a
real-world survival measure which is discussed in section 5.3.
Flexible parametric relative survival models
As described previously, this thesis focuses on estimation of relative survival via modelling. FPMs
can be implemented to estimate relative survival by utilising information from the expected
mortality [42]. These models work in a very similar way to the FPM as presented in equation
(5.2) but instead model the log cumulative excess hazard, Λ(t):
ln[Λ(t;x)] = s(α;γ0) + xβ . (5.14)
The cumulative excess hazard can be calculated in a similar way to the excess hazard shown
in equation (5.11):
Λi(t) = Hi(t)−H∗i (t). (5.15)
FPMs which model the log cumulative excess hazard can easily be extended to allow for
non-proportionality by including interactions in a similar way to those shown in equation
(5.3). Similarly to when modelling the log cumulative hazard using FPMs, maximum likelihood
estimation is used when using FPMs to estimate relative survival. The likelihood function is
written as follows [58]:
ln li = di ln[h
∗(t i) +λ(t i)] + ln[S∗(t i)] + ln[R(t i)].
Since S∗(t i) does not depend on any model parameters, the likelihood function can be
simplified in the following way:
ln li = di ln[h
∗(t i) +λ(t i)] + ln[R(t i)]. (5.16)
This means that the likelihood can be maximised by merging in the expected mortality rates at
the time of death without the need for numerical integration or time-splitting.
5.2.2 The expected survival/mortality
The expected survival is defined as the survival that would be expected had the cancer patients
not been diagnosed with cancer. Survival probabilities and mortality rates are often obtained
from nationwide population life tables [35, 59] and are matched to characteristics of the cancer
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patients. Such expected survival probabilities or mortality rates are used when calculating
relative survival.
In order to interpret relative survival as net survival, we make two assumptions as previously
stated, 1) that the all-cause survival and the expected survival are conditionally independent
given certain variables, usually age, sex and calendar year, and 2) that the expected survival
is representative of what the cancer patients would have experienced had they not have had
cancer. In practice, there are many variables other than age, sex and calendar year that both the
all-cause survival and the expected survival differ by, for example the presence of comorbidities
or SES. However, this is usually only problematic if one wishes to quantify relative survival
by one such variable, but does not have expected mortality rates adjusted by that variable
[60, 61], thus violating assumption 2. For example, suppose one is interested in estimating
relative survival by SES where SES-specific life tables are not available. In truth the expected
mortality is higher for the low SES, and lower for the high SES than the expected rates available.
If relative survival is estimated by SES using life tables without consideration of SES, the relative
survival for the low SES group will be an underestimate, and the relative survival for the high
SES will be an overestimate.
In Study III we present methodology which can utilise information contained in control
populations to further adjust expected mortality rates. Previous work in creating adjusted life
tables includes using data available for the whole population [62, 63, 64], modelling grouped
data [65] or using available mortality and prevalence information [62, 66, 67]. Alternatively,
Howlader et al. suggest using a cause-specific approach instead of a relative survival approach
if appropriate life tables are not available [68].
One other consideration when using expected survival from population life tables for the
estimation of relative survival, is that the cancer patients under study are commonly included
in the general population used to estimate the expected mortality. This would imply that the
expected mortality is slightly higher than it should be if the cancer patients had been excluded,
but in practice, this inclusion of cancer patients makes little difference to relative survival
estimates of specific cancers [69].
5.3 The loss in expectation of life
Relative survival as an estimate for net survival has great advantages for comparing cancer
patient survival between different groups. The interpretation of relative survival as an estimator
of cancer patient survival if cancer patients could only die of their cancer is, however, difficult
to grasp since it is a hypothetical situation. In contrast, such ‘real-world’ measures as the LEL
can be estimated to compliment estimates of relative survival, or to answer a different question
about the impact of a cancer diagnosis in the real-world.
The LEL gives a measure of the life years lost to disease, or the reduction in the life ex-
pectancy due to disease; in this thesis we focus on the effects of a diagnosis of cancer. In
comparison to net survival, the LEL can be offered as an intuitive measure which quantifies
survival over patients’ whole life span. The simple interpretation of LEL could be useful for
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non-statisticians understanding of the effect of a disease and the probable prognosis of dis-
eased patients. The interpretation remains simple even when complex modelling is required
to capture underlying patterns in survival data. It can also be used to both quantify the burden
of cancer in society and on average for an individual.
The LEL is calculated as the difference between the life expectancy in a cancer-free popula-
tion and that in a cohort of cancer patients matched by age, sex and year; again the general
population is used as a proxy for this former value. Life expectancy, also known as mean survival
time, is calculated as the area under the survival curve:
Life expectancy =
∫ ∞
0
S(t)d t, (5.17)
where the survival curve continues until time reaches infinity. Letting x denote covariates, of
which x′ are the covariates also in the population life table and are a subset of x, the LEL can
be written as:
LEL(x) =
∫ tmax
0
S∗(t,x′)d t −
∫ tmax
0
S(t,x)d t. (5.18)
S(t,x) is the all-cause survival in the cohort of cancer patients, and S∗(t,x′) is the expected
survival, or, the all-cause survival in the general population. The two integrals in this equation
calculate the life expectancy in the general population and the life expectancy in the cohort of
cancer patients, thus quantifying the change in the life expectancy associated with a diagnosis
of cancer. Instead of integrating to infinity as shown in equation (5.17) for the life expectancy,
the LEL contains integrals between zero and a specified time tmax where both the survival
functions S(t,x) and S∗(t,x′) are assumed to be zero. Calculation of the LEL is illustrated in
Figure 5.2.
5.3.1 Extrapolation of survival curves
In order to calculate the integrals in equation (5.18), we require the population to have been
followed for long enough so that the survival has reached zero. This can be problematic since
follow-up is often too short to observe all deaths, thus, extrapolation of the survival curve is
undertaken. We can make reasonable assumptions about the expected survival extrapolation,
either using predictions for the future, or by assuming that the expected survival in the future
years will be the same as that in the most recently observed year. Extrapolation of the survival
within the smaller and more specific cohort of cancer patients is more problematic. One method
of extrapolating the all-cause survival of the cancer cohort is to fit a parametric model to the
observed all-cause survival based on the data that is available and extrapolating that curve.
However, even if this model fits well to the observed data, it may extrapolate poorly [70].
Hakama and Hakulinen suggested extrapolating the relative survival and then combining with
expected survival instead by using the relationship described in equation (5.10) [71]. In order
to extrapolate using relative survival, the LEL equation in (5.18) can be re-written in the
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Figure 5.2: Illustration of how the LEL is estimated. (a) shows the all-cause survival observed in the
cancer patients; the area under the curve represents the life expectancy, or mean survival, of the cancer
cohort. (b) shows the expected survival taken from the general population and the life expectancy of this
group as the area under the curve. (c) shows the LEL as the difference between the two life expectancies
shown in (a) and (b).
22
5. Statistical methods and measures
following way:
LEL(x) =
∫ tmax
0
S∗(t,x′)d t −
∫ tmax
0
S∗(t,x′) · R(t,x)d t, (5.19)
and can extrapolate relative survival for the estimation of LEL in one of the following three
ways:
• Assumption 1: Assume that the excess hazard is zero after a certain time point.
This is the same as assuming a point of statistical cure. This is implemented by fitting
a flexible parametric cure model [72]. The excess hazard is zero after the point of cure,
resulting in a constant cumulative excess hazard after the point of cure. Thus, the FPM
used to extrapolate relative survival when using the statistical cure assumption, imposes
this constraint that the cumulative excess hazard is a constant after the last knot in the
model.
• Assumption 2: Assume that there is a non-zero, constant excess hazard after a
certain time-point. In this FPM, the cumulative excess hazard can increase after the last
knot, but is constrained to increase in a constant way.
• Assumption 3: Assume that the log cumulative excess hazard follows the linear
trend predicted by the model. The use of RCSs in FPMs means that the function is
linear after the last knot; this assumption extends this linear function into the future.
Hakama and Hakulinen suggested, outside of the FPM methodology, that the extrapolation
of relative survival be implemented by assuming either the first or second assumption listed
[71]. Andersson et al. subsequently suggested using an FPM-based approach to model the
log excess cumulative hazard using these two extrapolation methods and additionally via the
linear trend predicted by the model [70]. Andersson et al. also showed that the FPM approach
is accurate for a variety of cancers for the assumption of cure, provided this is a reasonable
assumption for the particular cancer of interest, and when extrapolating based on the linear
trend estimated from the model. The extrapolation of relative survival works better than the
extrapolation of all-cause survival since, for most cancers, the excess mortality is highest early
on, and is low after a number of years. Thus, after a number of years, the extrapolation is driven
by the expected survival extrapolation which is easier by making reasonable assumptions. Note
that extrapolation via this method may not be advisable if the excess mortality is not low and
decreasing towards the end of the available follow-up. This is also illustrated by Figure 5.3
which shows an example of the extrapolation.
The LEL as described by Andersson et al. has been implemented in studies involving breast
cancer patients in the UK [73], for Swedish AML patients [74], among invasive cancer patients
in Australia [75], and in colon cancer patients [76], in addition to those discussed within this
doctoral thesis. Studies II and IV implement the approach by Andersson et al. where the linear
trend is extrapolated.
23
5. Statistical methods and measures
Relative survival
Observed
all−cause survival
Expected survival
0.0
0.2
0.4
0.6
0.8
1.0
Su
rv
iva
l p
ro
po
rti
on
0 5 10 15 20 25 30
Time since diagnosis (years)
Figure 5.3: Example of relative survival extrapolation compared to observed all-cause survival extrapo-
lation. The shape of the relative survival curve is easier to capture due to low excess mortality after a
number of years in comparison to the observed all-cause survival.
The LEL is presented here as a cancer-specific measure. It is possible to quantify the reduc-
tion in the life expectancy for other diseases, but the assumptions made using the methodology
in the cancer setting to estimate the LEL may not be reasonable in other diseases. Estimating the
LEL in the way described in this thesis relies on the assumption that the cancer patients would
experience the survival seen in the general population if they had been cancer-free. Using the
general population in this way has been shown to not be problematic for most cancers but may
not be reasonable when considering other diseases. For example, this assumption may not be
appropriate for patients with coronary heart disease since they have a higher prevalence than
the general population of other comorbidities and risk factors which could result in death due
to causes other than coronary heart disease [77].
5.3.2 Measures related to the loss in expectation of life
There are several methods which are closely related to the LEL, or that aim to estimate a similar
quantity [78]. Measures which estimate the impact a diagnosis has on the potential life span
include the years of life lost (YLL). This is a measure which is closely related to the LEL. The
YLL estimates the impact a diagnosis of cancer has via the number of life years lost due to
cancer. This can be calculated in several different ways. Burnet et al. describe the YLL as the
difference between the age at cancer death and the life expectancy for someone of the same
age [79]. Equivalently this can be calculated as the number of deaths multiplied by the life
expectancy at the age of death [80, 81]. One problem with calculating the YLL in this way is
that it will never be zero since the life expectancy is calculated conditional on surviving until
the age of interest. Mettlin et al. describe an alternative way to calculate the YLL in which the
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age at death is subtracted from a set cut off age, where 65 years has commonly been used as
the cut off [82, 83]. Any deaths after the cut-off age contribute nothing to the YLL. Selecting a
relevant cut-off age for this method is arguably subjective. Although the LEL and the YLL are
similar in that they aim to quantify premature mortality and both account for changes in both
the cancer-mortality and the mortality in the general population, there are some additional
weaknesses of the YLL [84]. Specifically, YLL relies on correct cause of death information which
would be problematic if death information is not reliable. It also disregards any treatment-
related deaths. However, even if cause of death is accurate, the measure cannot be used for
a specific cohort since it can only be calculated for those patients who have died. This also
means it is not optimal for considering the potential prognosis of patients [83]. On the other
hand, one strength of the YLL is that it can be used for diseases other than cancer since it is
not calculated based on the same assumptions as the LEL.
Other measures that are included in this thesis in Study IV are the proportion of expected
life years lost (PELL), total life years lost, gain in life years, and the postponable deaths. A
generalised summary of these measures and the LEL are presented in Table 5.2. The PELL is
calculated as the LEL divided by the life expectancy that would have been expected had the
patient not been diagnosed with cancer. Whilst the LEL is highly age dependent since younger
ages have more remaining life years to potentially lose, the PELL is a measure which is more
comparable over different ages [85]. The total life years lost is the LEL multiplied up, e.g.,
by the number of cases diagnosed in a calendar year. This quantifies the loss on a population
level and provides a measure of cancer burden on the whole population. Both the gain in life
years and the postponable deaths require a counterfactual situation that can be compared to
the actual observed data. For example, in Study IV we compare the LEL estimated from the
observed data, to the LEL that would have been estimated had the relative survival been the
same in all education groups. In this way we can determine the potential effects of eliminating
differences in education group between the number of life years lost (estimated by the LEL),
or the number of deaths (postponable deaths). The gain in life years can also be multiplied
up to provide a population-level measure. Note that postponable deaths are often also called
avoidable deaths. The term postponable was chosen to indicate that the measure is highly
time-dependent and that no death is truly avoided if followed up for a long enough time.
One interesting observation by Rutherford et al. was that the postponable deaths mea-
sure and the LEL are related [86]: the gain in life years can be calculated by integrating the
postponable deaths as so:
Gain in life years =
∫ tmax
0
S∗(u)du−
∫ tmax
0
R(u) · S∗(u)du

−
∫ tmax
0
S∗(u)du−
∫ tmax
0
Ral t(u) · S∗(u)du

=
∫ tmax
0
R(u) · S∗(u)du−
∫ tmax
0
Ral t(u) · S∗(u)du
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=
∫ tmax
0
S∗(u) [R(u)− Ral t(u)]︸ ︷︷ ︸
= postponable deaths
du. (5.20)
Measure Quantifies Equation
Life years lost or loss in
LEL
life expectancy
see section 5.3
Proportion of remaining life years lost
PYLL
due to the diagnosis of cancer
PYLL = LELExpected remaining life years
Total LYs lost Total life years lost
(TLYL) in population
TLYL = N · LEL
Gain in LYs Gain in LYs if an alternative
(GLY) situation was experienced by patients
GLY = N · (LELal t − LEL)
Postponable Postponable deaths if an alternative
deaths (PD) situation was experienced by patients
PD = N · {[Ral t(t)− R(t)] · S∗(t)}
LELal t and RSal t refer to the LEL and relative survival, respectively, that would be estimated under an alternative
or counterfactual situation. N is the number of individuals at risk.
Table 5.2: Description of measures related to the LEL that are estimated in Study IV.
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6.1 Study I
Study I of this thesis is titled Capturing Simple and Complex Time-Dependent Effects Using Flexible
Parametric Survival Models: A Simulation Study and focuses on 1) assessing the ability of RCSs
in FPMs in capturing time-dependent effects, 2) comparing this ability when modelling the log
hazard and the log cumulative hazard, and 3) determining whether model selection for FPMs
should be based on the AIC or the BIC.
6.1.1 Motivation
FPMs are becoming more popular for modelling survival data as an alternative to the Cox
model and other parametric models. This is due to their ability to model the baseline function
in a flexible way. Although these models have been assessed under the proportional hazards
assumption [43], it is common for this assumption to be violated. Users of FPMs often rely on
information criterion, usually the AIC and/or the BIC to select the optimal number of degrees
of freedom, but it is not clear if one method outperforms the other.
6.1.2 Simulation strategy
We simulated time-to-event data under nine scenarios with differing complexities. These nine
scenarios were a combination of three different baseline hazard functions and three different
time-dependent functions. The scenarios were denoted 1A-1C, 2A-2C, 3A-3C where the base-
line hazard used was denoted by the numbers 1-3 and the letter referred to the time-dependent
effect. Note that the paper includes scenarios 1-3 which are scenarios 1A, 2B, and 3C, respec-
tively. Baseline functions were taken from Rutherford et al. Time-dependent effects are shown
in Figure 6.1 where the underlying HR is a function of time. The survival times were simulated
using methods discussed in Bender et al. [87] and subsequently Crowther et al. [88]. Hazard
functions for both levels of the binary covariate x are shown in Figure 6.2.
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Figure 6.1: Time-dependent effects included in the simulation scenarios. (a) shows the time-dependent
effect in scenario A simulated using a real time-dependent effect of deprivation status found in breast
cancer patients [89]. (b) shows the time-dependent effect used in scenario B which is based upon an
effect seen for stage in colon carcinoma patients [90]. (c) shows the time-dependent effect used for
scenario C based on a fictional effect [91].
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Figure 6.2: The hazard rates from nine simulated scenarios.
FPMs were fitted to the simulated data sets with varying degrees of freedom. Survival
proportions, hazard rates and HRs were predicted from these models and the AIC and BIC
calculated; see Table 6.1 for a summarised description of the simulation strategy. We assessed
the performance of each model by comparing the predictions to the true values and calculated
the bias, root mean square error, and coverage for each degrees of freedom selected. Bias is
defined as the difference between the expected value of an estimator and its true value whereas
root mean square error reflects the spread of the estimates. Coverage measures the proportion
of the total number of simulations where the confidence interval contains the true value.
We wished to utilise the fact that we knew the truth in this simulation setting by also
assessing how appropriate model selection by the AIC and BIC was. To do this we calculated
a measure called the Symmetrised Kullback-Leibler distance (SKL). The fitted model with the
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Number of
simulations
500
• 1,000
Sample size
• 10,000 (only for models on the log cumulative hazard scale)
FPMs with all combinations of 3,5,7 degrees of freedom for the
baseline & 1,3,5,7 degrees of freedom for the time-dependent
effect on the:
• log cumulative hazard scale
Models fitted
• log hazard scale
• log HR at 1, 3, and 5 years
• hazard rates at 1, 3, and 5 yearsEstimates of interest
• survival proportions at 1, 3, and 5 years
Table 6.1: Summary of the simulation strategy.
smallest SKL is the model closest to the truth. In the context of hazard estimation, the SKL can
be written as [92]
SKL(hˆ, h) =
1
n
n∑
m=1
∫ Tm
T0m
ln

h(t, Xm)
hˆ(t, Xm)

h(t, Xm)− hˆ(t, Xm)

d t, (6.1)
where t is time, T0m and Tm are the entry and exit times respectively, and Xm represents the
covariates for each observation m = 1,2, ..., n. The SKL measures the difference between the
fitted model and the true model [93, 94, 95]. We compared the optimal model, i.e., the optimal
degrees of freedom, chosen by the AIC and the BIC to that selected by the SKL in order to
determine which of the two information criteria were more accurate. Note that the SKL can
only be calculated in a setting where the underlying truth is known.
6.1.3 Main results
Outside of a simulation setting, it is common that the degrees of freedom chosen when mod-
elling using an FPM would be based on the values of the AIC and/or the BIC. Thus, Table 6.2
and Table 6.3 summarise the main results from this study by presenting bias from the models
that were chosen by the AIC and the BIC. Note that this means that the optimal degrees of
freedom chosen by the AIC could be different for different simulated datasets; similarly for the
degrees of freedom chosen by the BIC. Tables 6.2 and 6.3 show the absolute bias of predictions
estimated from models on the log cumulative hazard scale for 1,000 and 10,000 observations,
respectively. The results show that the bias overall was low for all scenarios when using the
AIC- and BIC- selected model. Bias increased, but was still small, when considering the log HRs
in comparison to the survival proportions. At the same time, bias in the log HR was lower when
using 10,000 observations in comparison to using 1,000 observations. For example, the bias in
the log HR for scenario 3C at time t = 5 was 0.089 when using the AIC for 1,000 observations.
When calculating this based on 10,000 observations, the bias reduced to 0.041. Bias in the
hazard rates and log HRs also generally increased with time. It is important to remember that
follow-up ended at five years, thus it may be reasonable for the models to perform less well at
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five years.
AIC model, absolute bias BIC model, absolute bias
t S0(t) S1(t) h0(t) h1(t) logHR S0(t) S1(t) h0(t) h1(t) logHR
1 0.000 0.000 0.005 0.002 0.004 0.002 0.000 0.004 0.002 0.003
3 0.000 0.000 0.002 0.001 0.003 0.001 0.001 0.002 0.001 0.0031A
5 0.000 0.000 0.006 0.003 0.007 0.000 0.000 0.006 0.004 0.005
1 0.001 0.002 0.003 0.006 0.007 0.004 0.004 0.023 0.016 0.020
3 0.002 0.002 0.029 0.006 0.003 0.005 0.005 0.047 0.004 0.0122B
5 0.000 0.000 0.002 0.011 0.027 0.002 0.000 0.040 0.014 0.085
1 0.000 0.000 0.001 0.001 0.010 0.008 0.010 0.006 0.000 0.002
3 0.000 0.000 0.003 0.002 0.021 0.004 0.001 0.030 0.012 0.1923C
5 0.000 0.001 0.011 0.002 0.089 0.000 0.000 0.032 0.001 0.184
Table 6.2: Summary of the absolute bias in the survival proportions, hazard rates and log HRs for models
on the log cumulative hazard scale using degrees of freedom selected by the AIC and BIC; based on
1,000 observations. Here the notation S0(t) refers to the survival at time t estimated for x = 0. Results
are presented to three decimal places.
AIC model, absolute bias BIC model, absolute bias
t S0(t) S1(t) h0(t) h1(t) logHR S0(t) S1(t) h0(t) h1(t) logHR
1 0.001 0.000 0.000 0.000 0.000 0.002 0.001 0.001 0.001 0.000
3 0.000 0.000 0.002 0.000 0.002 0.000 0.001 0.002 0.000 0.0021A
5 0.001 0.000 0.004 0.000 0.005 0.001 0.000 0.004 0.002 0.004
1 0.000 0.000 0.019 0.002 0.001 0.002 0.001 0.015 0.004 0.002
3 0.000 0.001 0.018 0.007 0.008 0.001 0.002 0.021 0.007 0.0062B
5 0.000 0.000 0.018 0.010 0.017 0.000 0.001 0.012 0.011 0.029
1 0.001 0.001 0.003 0.001 0.001 0.000 0.000 0.007 0.004 0.003
3 0.000 0.000 0.000 0.002 0.010 0.000 0.000 0.001 0.003 0.0083C
5 0.000 0.000 0.009 0.001 0.041 0.000 0.000 0.010 0.001 0.044
Table 6.3: Summary of the absolute bias in the survival proportions, hazard rates and log HRs for models
on the log cumulative hazard scale using degrees of freedom selected by the AIC and BIC; based on
10,000 observations. Here the notation S0(t) refers to the survival at time t estimated for x = 0. Results
are presented to three decimal places.
6.1.4 Log hazard versus log cumulative hazard
One thing we were particularly interested in was whether modelling on the log cumulative
hazard scale outperformed modelling on the log hazard scale. Due to the numerical integration,
models on the log hazard scale took longer to fit and there were more convergence issues on
this scale. For these reasons the analyses for 10,000 observations were restricted to modelling
on the log cumulative hazard scale. Since this study, more work has been put into optimising
the numerical integration in the strcs command in Stata which has improved both the speed
and convergence, but there do still remain disadvantages to modelling on the log hazard scale
in comparison to the log cumulative hazard scale. In terms of bias, slightly larger biases were
present on the log hazard scale in comparison to the log cumulative hazard scale. However,
these remained small when considering the AIC- and BIC- selected models. Moreover, it is
important to remember that more degrees of freedom will be required to model a hazard
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function in comparison to a cumulative hazard function. The results in this study did not
necessarily indicate that modelling on the log cumulative hazard scale should be preferred,
which was reassuring when considering our next methodological developments were planned
for FPMs which model the log hazard function.
6.1.5 Discussion
The results from this simulation study indicate that FPMs accurately capture time-dependent
effects, but that some thought into the selection of the degrees of freedom is required in order to
avoid biased results, especially if one is interested in hazard rates or HRs. It is also important to
remember that some scenarios included in this study were chosen purposely to be extreme, i.e.,
the time-dependent effect C. Guidance for users in selecting the degrees of freedom is important
so we aimed to provide this via the section Advice for users of flexible parametric survival models
in the paper. However, extensions of these recommendations may be advantageous to users,
especially new users. Such advice is highly important when the user decides what complexity
of model they will fit to their data.
In the same manner, FPMs have been criticised for 1) the need to select the degrees of
freedom, and 2) the need to select the knot positions. Although we did not examine knot
positions in this study, these are commonly placed at evenly distributed percentiles of the event
times [42] and it has been shown that unless extreme choices are made, changing the knot
positions rarely makes a difference to the model estimates [36, 42]. This conclusion is similar to
our findings considering the selection of the degrees of freedom, i.e., that unless extreme values
in the degrees of freedom are chosen, changing the number of knots makes little difference to
the model estimates, particularly the survival proportions. As an alternative to making these
selections, one could use penalised methods which do not require the user to select the knot
positions and the number of knots. However penalised methods still rely on the user selecting
a maximum degrees of freedom [96]. Comparisons between FPMs using the AIC to select the
degrees of freedom and penalised methods show that both work well in capturing effects from
data with proportional hazards [96].
On the other hand, the selection of knots does not need to be a weakness of these methods
if appropriate model selection is undertaken. Selection of degrees of freedom being guided by
the AIC and/or the BIC can be seen as a positive aspect of these models. Sensitivity analyses are
always required to ensure that the conclusions are not sensitive to the model selected and by
performing FPM analyses as suggested, fitting several models and comparing the information
criterion to help select a good model, sensitivity analyses are built into the model-selection
process. Seeing that the results and conclusions do not change based on a reasonable choice
of the degrees of freedom is a positive thing that users should want to state.
There remain several disadvantages associated with this simulation study. One of the main
disadvantages is the selection of the variable with the time-dependent effect. In our simulation
study, we created a binary variable with a time-dependent effect. This limits the implications of
the results since real-data analyses may 1) have more than one variable with a time-dependent
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effect, and 2) have non-binary variables with a time-dependent effect. Performing a simulation
with more time-dependent effects of other types of variables is a potential extension of this
work, but we believe that this study remains essential for implementations of FPMs in data
where proportional hazards is not a reasonable assumption.
6.1.6 Conclusion
Generally, the results indicated that FPMs capture simple and complex effects under non-
proportional hazards and that the selection of degrees of freedom should be guided by both
the AIC and the BIC. Modelling on both the log cumulative hazard and log hazard scales per-
formed equally well. Users should remember to use both information criteria to help guide
their selection and remember that many models will fit well. It is also advisable to ensure that
the model selected captures patterns, in say the hazard function, that seem reasonable for the
subject area. The results from this study offer reassurance to users of FPMs who are using these
as tools for modelling complex data which often has non-proportionality. Although further
work into multiple time-dependent effects with differing complexities is desirable, this work
is a necessary assessment of FPMs which also offers an insight into the process of fitting these
models for current and potential new users.
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6.2 Study II
Study II titled Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life
Expectancy of the General Population is an application of the LEL to Swedish CML patients.
6.2.1 Motivation
CML is a slow growing leukaemia which can become fatal if not treated. Consequently, most
patients currently take CML treatments over their whole lifetime. A previous study by Björkholm
et al. [11] showed that the relative survival of CML patients diagnosed after 2001 in Sweden
was greater in comparison to previous calendar years, and concluded that this improvement
was mainly due to the introduction of the treatment IM in 2001. Since CML is a chronic disease,
it is highly interesting to see how these changes in treatments translate into changes in the life
expectancy via the LEL.
6.2.2 Materials and methods
The data used for this analysis comprised of 2,662 Swedish CML patients diagnosed between
1973 and 2013. This data was obtained from the SCR. Patients were followed from their date
of CML diagnosis until their date of death, emigration date, or end of follow-up (31 December
2013); whichever came first. We included patients who were aged 50 and above at diagnosis.
This was because extrapolation of relative survival in patients younger than 50 years at diagnosis
has not been studied [70].
FPMs were fitted with five degrees of freedom to model the baseline log excess cumulative
hazard. Main effects of age at diagnosis (RCS with four degrees of freedom), year of diagnosis
(RCS with four degrees of freedom) and sex were included in the model. Interactions between
year of diagnosis and age at diagnosis, sex and year of diagnosis, and sex and age at diagnosis
were modelled. Time-dependent effects of age at diagnosis, year of diagnosis and sex were
also included. Only the linear RCS term of continuous variables were included in interactions
and time-dependent effects. The extrapolated relative survival was estimated using the linear
predictor from this model (assumption 3 described in section 5.3.1) and was then multiplied
by the expected survival to get the observed survival. The expected survival was obtained from
the mortality in the Swedish population available until 2012, and extrapolated by Statistics
Sweden. We used an FPM to model relative survival and subsequently predicted the LEL and
the proportion of expected life lost from this model.
6.2.3 Main results
The main results are shown in Figure 6.3, where the remaining life years, or remaining life
expectancies, of CML patients and the general population are presented over year of diag-
nosis, by age and sex. This figure shows that there have been vast improvements in the life
expectancy over calendar period, with improvements beginning in early 1990s for younger
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patients, and improvements beginning mid- to late-1990s for the older patients. These im-
provements increase for all patients until they reach almost the same life expectancy as the
general population in 2013, with predictions indicating that patients diagnosed with CML in
2013 will lose approximately three of their remaining life years lost due to their diagnosis of
CML.
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Figure 6.3: The remaining life expectancy of the general population and Swedish CML patients over
year of diagnosis by sex and age at diagnosis.
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6.2.4 Sensitivity analyses
Modelling assumptions can often be criticised without relevant sensitivity analyses. One sen-
sitivity analysis that we undertook was to determine the effect that changing the degrees of
freedom had on the results. We altered the degrees of freedom used to model both the baseline
log cumulative hazard and the time-dependent effects. Figure 6.4 shows the effect of this on the
LEL for patients diagnosed with CML over calendar year. This figure shows that for those aged
75 and 85 years at diagnosis, the results were insensitive to changes in the degrees of freedom.
For those aged 55 and 65 years, changing the degrees of freedom made little difference to the
life years lost up until approximately year 2000. After year 2000, changing the degrees of free-
dom made a small difference to the life years lost. These small differences seemed to be driven
by changes in the degrees of freedom chosen to model the time-dependent effects rather than
the baseline. The conclusions drawn in the paper are insensitive to these changes with perhaps
the exception of the results seen for those aged 65 using one degree of freedom to model the
time-dependent effect. The model with one degree of freedom for the time-dependent effect
suggested that the LEL begins to level off for those aged 65 years. Both the AIC and the BIC
values indicated that the best fitting models required more than one degree of freedom for the
time-dependent effect and thus, this is likely an effect of undermodelling.
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Figure 6.4: LEL for males and females diagnosed with CML over calendar year. Results are shown for
models with differing degrees of freedom (df) where the first number refers to the degrees of freedom
used to model the baseline log cumulative hazard and the second number refers to the degrees of
freedom used to model time-dependent effects.
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6.2.5 Discussion
Previous studies in this area have quantified survival of CML patients using relative survival.
Björkholm et al. concluded that ‘major improvement’ was seen during the period 2001-2008
mainly due to to the use of IM [11]. Although both our study and the study undertaken by
Björkholm et al. saw improvement from the early 1990s, we did not observe such a vast im-
provement in the life expectancy or LEL from 2001 when IM was introduced. It is important
to remember that relative survival and LEL measure different aspects of cancer patient sur-
vival, and these differences could have contributed to these inconsistencies. Furthermore, it is
possible that this difference could have been affected by how calendar year was modelled in
the two studies. We modelled calendar year continuously using an RCS, whereas Björkholm
et al. categorised calendar year; categorising can hide effects which would be seen otherwise
when using a continuous variable. We additionally calculated the relative survival to extend
the analyses undertaken by Björkholm et al. with follow-up until 2013; see Figure 6.5 for the
five-year relative survival over time since diagnosis. Improvements prior to 2001 are seen when
modelling year continuously which illustrates how modelling selections can make differences.
Nevertheless, the introduction of IM had a large part in the improvements shown in the study
by Björkholm et al. and Study II, and modelling calendar year continuously or via categories
would not have altered these conclusions.
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Figure 6.5: Five-year relative survival ratio over calendar year by age and sex.
Our study shows great improvements over time for CML patients in Sweden, but this does
not mean that work in treating these patients is over. More research is needed to assess potential
negative late effects of IM; lack of follow-up in our study means assessing this was not possible.
Such problems seem plausible since there have been studies which have found an increased
risk of cancer [97] and cardivascular deaths [98] involved in such treatments. This means that
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the life expectancy of CML patients may never actually reach that of the general population.
There also remains a subset of patients who are diagnosed in the acute phase who have an
inferior response to targeted treatments such as IM [99]. It is also important to consider that
the results presented in Study II may not be applicable outside of Sweden since individuals in
other countries may not have the same sort of access to healthcare [100].
Another implication of these results is the impact on the Swedish healthcare system. Al-
though incidence of CML has remained stable over the years, the survival gains have resulted
in an increase in the prevalence of CML in Sweden. Although this could suggest a large eco-
nomic increase for the Swedish healthcare system, Ohm et al. found that IM would pass cost-
effectiveness levels accepted by healthcare authorities. Furthermore, there has been a recent
focus on the possibility of discontinuation of targeted therapies like IM in CML patients. Clnini-
cal trials in this area show that it is possible to safely discontinue IM in well-responding CML
patients [14, 101].
6.2.6 Conclusion
This study illustrates how life expectancy and LEL can be presented to better understand
cancer prognosis in a population. CML patients diagnosed in the most recent calendar years
are expected to lose, on average, around three years of their remaining life due to their diagnosis
of CML, a vast improvement in comparison to previous calendar years which is largely due to
treatment advances.
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6.3 Study III
Study III presents methodology for adjusting expected mortality rates by additional variables
that are available within a control population. The publication is titled Adjusting Expected
Mortality Rates Using Information From a Control Population: An Example Using Socioeconomic
Status.
6.3.1 Motivation
Expected mortality rates are often used as a comparitive rate for diseased patients. To accurately
estimate measures such as relative survival, LEL, and standardised mortality ratios, expected
mortality rates must be representative of the diseased population had they not been diseased.
Analyses may be limited to quantifying these measures by age, sex, calendar year, and disease-
specific factors since expected mortality rates from the population are often only presented
for the former three factors. If analyses are performed by other factors which the expected
mortality rates are additionally expected to vary by, then bias may occur. Although information
additional to age, sex and calendar year are often unavailable on a population level, control
populations that represent a random subset of the general population may be available with
such data. We provide methods to adjust expected mortality rates by additional factors by
utilising information contained in an available control population.
6.3.2 Developed methodology
Using SES information in the form of highest education achieved (low, medium, high) from
333,212 controls in BCBaSe, we adjusted Swedish population mortality rates using two different
methods, 1) a Poisson approach, and 2) an FPM approach. Both approaches aimed to estimate
the difference in mortality rates between the whole population of Sweden, h∗, and the control
population in BCBaSe, hc , and to quantify these differences by SES. In this way, one can estimate
a value (adjustment factor, ρ) that the population mortality rates must be multiplied by to get
SES-adjusted rates.
Equation (6.2) illustrates how the SES-specific adjustment factors ρ j for different SES
groups j, can be estimated as a function of attained age a and attained year y using the
expected rates in the control population and the general population.
hc(a, y, j)
h∗(a, y) = exp
 3∑
j=1
ρ j(a, y) · SES j
 (6.2)
Rearranging this equation illustrates how we estimated the adjustment factors in the Poisson
and the FPM by modelling the rates in the control population, and including an offset of the
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mortality rate taken from the general population:
ln[hc(a, y, j)] =
3∑
j=1
ρ j(a, y) · SES j + ln[h∗(a, y)]. (6.3)
Note that there is no constant term, or baseline coefficient, included in the model and that all
SES indicators are included with coefficients. This is so that we can directly estimate the effect
of each SES group on the difference between the two mortality rates, i.e., directly estimate the
adjustment factors.
Poisson model approach
We split on both the attained age and the calendar year timescale for the Poisson approach and
modelled the rates in the control population in a similar way to the Poisson model presented
in equation (3.4) by modelling the number of deaths, and including an offset for the person-
time at risk. Consequently the Poisson model approach included two offsets. The first offset
contained the person time at risk in order to allow modelling of rates rather than counts, and
the second contained the expected mortality rate found in the general population in order to
estimate the adjustment factors.
Flexible parametric model approach
The FPM approach applied in this study was undertaken using the strcs command I developed
in Stata [45] which models on the log hazard scale. In order to estimate an adjustment factor
for each of the SES groups, and not model the baseline log hazard, we first smoothed the
expected mortality rates taken from the general population, and constrained the baseline log
hazard spline function in the FPM. This worked in the following way:
1. Smooth the expected mortality rates in the population life table as a function of attained
age and attained year (here h∗s (a, y) represents the smoothed expected mortality rate
found in a population life table):
ln[h∗s (a, y)] = sa(a;γa) + sy(y;γy). (6.4)
2. Model the difference between the expected mortality rate and the mortality rate in the
control population (in order to estimate adjustment factors) using an FPM:
ln[hc(a, y, j)] =
3∑
j=1
ρ j(a, y) · SES j + ln[h∗s (a, y)] (6.5)
=
3∑
j=1
ρ j(a, y) · SES j + sa(a;γa) + sy(y;γy) (6.6)
where the third term in equation (6.6), sa(a;γa), is the baseline spline function described
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in equation (5.6) but is constrained to be the the spline function in the smoothed rates
model (6.4). The fourth term, sy(y;γy), is also forced to be the same as the spline in
equation (6.4). Applying constraints in this way allows the FPM to estimate adjustment
factors as required. Note that in general this means that at least one of the continuous
variables in equation (6.4) must be modelled using RCSs.
Relative survival of Swedish breast cancer patients
We used the two described methods to adjust expected mortality rates by SES. We then used
these SES-adjusted expected mortality rates, plus the unadjusted rates, to estimate relative
survival of female breast cancer patients recorded in BCBaSe. Consequently, FPMs were fitted
to model the log excess cumulative hazard function using 1) original unadjusted expected
mortality rates, 2) SES-adjusted expected mortality rates estimated from the Poisson approach,
and 3) the SES-adjusted expected mortality rates estimated from the FPM approach.
Uncertainty of estimates using adjusted expected mortality rates
It is common to assume that mortality rates contained in population life tables carry no uncer-
tainty since they are calculated from the whole population. It has been shown that making this
assumption makes little difference to the variance of model-based relative survival estimates
[102]. However, there is additional uncertainty to account for when using adjusted life tables
(using the previously described methodology) in subsequent analyses. In this study we imple-
mented a parametric bootstrap method in combination with Rubin’s Rules [103] to account
for this additional uncertainty. We used these methods to estimate confidence intervals for
relative survival estimates of breast cancer patients contained in BCBaSe. We also selected 10%
and 1% random samples of the control population to determine the impact of smaller control
populations on the uncertainty in the relative survival estimates.
6.3.3 Main results
The main results from this study showed that both methods estimated similar adjustment
factors; larger differences were seen for ages below 50 years. These differences were not
seen in the SES-adjusted mortality rates since the mortality rates in those under 50 years was
low; see Figure 6.6. As expected, differences between the relative survival estimated using
SES-adjusted and non-adjusted expected mortality rates were seen, with the relative survival
estimates using unadjusted expected mortality rates overestimating the differences between
SES groups. Confidence intervals for five-year relative survival using the bootstrapping method
showed increased confidence intervals when using 1% of the control population (≈ 3000
individuals).
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Figure 6.6: (a) shows adjustment factors estimated from the Poisson approach, and the FPM approach.
Adjusted rates for the two approaches are shown in (b).
6.3.4 Sensitivity analyses
Several different sensitivity analyses were undertaken to determine the effect of the model
chosen to estimate the adjustment factors on 1) the resulting adjustment factors and 2) the
SES-adjusted mortality rates. These sensitivity analyses included changing the way the age
variable was modelled, changing degrees of freedom for the splines included in the models,
and investigating the effect of including interactions. We also considered how the estimates
altered when changing the model used for smoothing the unadjusted expected mortality rates.
Minor changes were seen in the SES-adjusted expected mortality rates when small changes
were made to both the models specified for 1) smoothing the unadjusted expected mortality
rates and 2) estimating adjustment factors. The adjustment factors were more sensitive to
model changes than the SES-adjusted rates. Most larger differences in the adjustment factors
were seen in younger individuals where fewer events occur, thus resulting in little difference
on the mortality scale.
One additional sensitivity analysis that we undertook was to determine both the effect of
the size of the time-splitting interval, and the effect of smoothing in the Poisson models. In the
paper we present two methods, but there are other ‘hybrid’ models that could be considered.
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Figure 6.7 illustrates these along with Table 6.4. The models presented in this figure and table
are Poisson models which either split time more finely, or use smoothed expected mortality
rates. Similar to previous findings, the adjustment factors on the left of Figure 6.7 were more
sensitive to these changes whereas the mortality rates on the right were fairly insensitive.
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Figure 6.7: (a) shows adjustment factors and (b) shows SES-adjusted mortality rates from sensitivity
analyses of the Poisson approach. Models are explained in Table 6.4.
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Model Control population timescales General population timescales
hc(a, y, j) h∗(a, y)
A Split yearly Split yearly
B Split monthly Split yearly
C Split monthly Smoothed rates
D Continuous Smoothed rates
Table 6.4: Description of each of the Poisson models in the sensitivity analysis presented in Figure
6.7. Note that model B is the Poisson model presented in the paper and that model D is the Poisson
equivalent of the FPM model, i.e., parameters in the adjustment factor model are constrained in order
to include the smoothed expected mortaltity rates.
6.3.5 Discussion
Potential users of these methods may wonder which of the two methods to use. We suggest
that individuals who may not be familiar with FPMs use the Poisson approach since this is
the simpler method to apply. Alternatively, if one is worried about computational speed, it is
advisable to use the FPM approach. As suggested in the sensitivity analyses presented here,
it is possible to use the Poisson model in a similar way to the FPM model by smoothing the
expected mortality rates and constraining estimates in the Poisson model. This method is a
good alternative for individuals who are not familiar with FPMs and are worried about the
computational speed involved in time-splitting. When the methods were being developed, the
Stata command strcs [45], did not allow for the inclusion of an interaction between SES and
year which could have easily been incorporated into the Poisson model.
One of the advantages to using the methodology described is that we utilise information
both from the control population and the general population. Using the information from the
general population reduces the uncertainty of our subsequent estimates of interest, for example,
five-year relative survival, in comparison to only using information from the control population.
Additionally, it is sensible to assume that the (SES-) adjusted expected mortality rates have a
similar shape to the shape found in the general population; we make this assumption when
utilising information from both the control population and the general population.
One of the greatest advantages to this methodology is that, contrary to the control pop-
ulation used in the publication, the control population need not be related to the diseased
population of interest. By control population we refer to a random subset of the general pop-
ulation whose information can be utilised. Control populations are used in many aspects of
research. These control populations could be utilised via these methods provided the control
population is representative of the general population of interest. The size of such control
populations should also be considered since very small control populations may not accurately
represent the general population and will increase uncertainty in subsequent analyses.
6.3.6 Conclusion
These methods offer the opportunity to further estimate survival measures by non-standard
variables. One only requires a control population that is representative of the general population,
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i.e., a random subset, that need not be matched to the diseased population. Analyses can be
limited by the lack of detailed factors on a population level and this work offers the possibility
for further research which quantifies estimates such as relative survival in terms of factors, for
example, SES, comorbidity and ethnicity.
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6.4 Study IV
Study IV titled Quantifying the Potential Gain in Life Years for Breast Cancer Patients in Sweden if
Differences Between Education Groups Could be Eliminated evaluated the impact that differences
in education level could have on the number of deaths and life years lost for Swedish breast
cancer patients. In this study, we attempted to answer such questions as ‘How many life years
could be saved if differences in stage at diagnosis between education groups could be removed?’,
and ‘How many deaths would we expect to avoid in a calendar year if differences in breast
cancer survival were removed between education groups?’.
6.4.1 Motivation and materials
It is known that survival differences exist between breast cancer patients with different SES, and
stage has been shown to play a role in these differences [24]. Measuring the survival outcomes
that could be gained if differences in SES were removed provides a greater understanding of the
impact of these differences. We aimed to quantify the impact of differences between education
groups in terms of the stage-distribution at diagnosis and stage-specific breast cancer survival.
62,121 breast cancer patients recorded in BCBaSe were used in the analyses. Highest
educational achievement data were available in BCBaSe and used as a measure of SES. Expected
mortality rates adjusted for education group were calculated using methods described in Study
III so that the cumulative excess hazards could be estimated by education group.
6.4.2 Statistical methods
Multiple imputation
After creating a combined stage variable from data in BCBaSe, around 12% of this stage variable
was missing. Additionally 3% of the education group information were missing. Falcaro et al.
illustrated that results can be biased when calculating relative survival using a complete case
analysis. Following their advice, we performed multinomial logistic regression using chained
equations for the imputation of missing stage and education group [104]. This imputation
model included age at diagnosis (RCS with three degrees of freedom), year of diagnosis (RCS
with three degrees of freedom), region, educational group, the event indicator, and the Nelson-
Aalen estimator of the cumulative hazard. We performed both a complete case analysis and
an analysis where we had performed multiple imputation (MI) where 30 imputed values for
each missing education group and stage value were created. Note that only the MI analysis is
presented in Study IV.
Modelling approach and measures estimated
We performed a period analysis using the period window 2008-2012 [105]. Thus, instead of
following all patients from their date of diagnosis until their date of death or censoring, we
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left-truncated the follow-up times at 2008 and censored them at the end of 2012; person-
time at risk only contributed to the analysis within this window. This method was chosen
since it provides better future estimates than a standard cohort approach [106] since patients
diagnosed recently contribute to the short term survival whereas long term survival is driven
by patients diagnosed further into the past. We fitted flexible parametric excess hazard models
to the breast cancer patients adjusting for age at diagnosis, stage at diagnosis and education
group. From these models we estimated the LEL, postponable deaths and gain in life years that
would have been expected under the following scenarios denoted methods A-C:
1. Method A: What if we could remove differences in the stage distribution between
education groups? To answer this question we replaced the age group-specific stage
distribution found in the low and the medium education groups with the age group-
specific stage distribution seen in the high education group.
2. Method B: What if we could remove differences in the breast cancer survival seen in
different education groups? We addressed this by replacing the age- and stage-specific
relative survival found in the low and medium education groups with the age- and stage-
specific relative survival seen in the high education group.
3. Method C: What if we could remove differences between education groups both in
terms of the stage distribution and the cancer-specific survival? This was approached
by combining methods A and B, and applying both the age-specific stage-distribution
and the age- and stage-specific relative survival of the high education group to the low
and medium education groups.
These three methods were used to estimate the effect of differences in educational group on
survival differences in breast cancer patients; see also Figure 1 in Study IV for clarification using
relative survival as an example. We applied these three different methods when estimating the
LEL, gain in life years, total life years lost and postponable deaths.
Standardised estimates
We stage-standardised estimates of relative survival (used for calculation of postponable deaths)
and estimates of the LEL. This was done in the following way for relative survival, and similarly
for LEL:
Rstage-stande,a (t) =
4∑
s=1
we,a,s ·Re,a,s(t) (6.7)
where we,a,s represented weights corresponding to the stage distribution in each age and educa-
tion group. This was calculated as we,a,s = ne,a,s/ne,a where n was the number of observations
in each e = 1,2,3 education groups, a = 1, ..., 6 age groups, and s = 1,2,3,4 stage groups.
This internal standardisation enabled us to provide one summary estimate of relative survival
for each education group (<40 years, 40-49, 50-59, 60-69, 70-79, and 80+ years) and age
whilst accounting for stage. Although age was categorised for the calculation of weights, age
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was otherwise used as a continuous variable, i.e., predictions of LEL were calculated for each
age separately. The total life years lost, total gain in life years and postponable deaths were
calculated by summing over (continuous) age and by using the number of individuals at risk
at each age. See the following section for further information on how these measures were
calculated.
Postponable deaths and total life years lost
Stage-standardised estimates of relative survival and LEL as calculated in equation (6.7) were
obtained for ages 21 to 99 years. We used the stage-standardised relative survival estimates to
calculate the postponable deaths (PD) for each education group, e, as follows:
PDe(t) =
99∑
a=21
Ne,a ·
¦
[Re,a(t)−Re,a(t)] · S∗e,a(t)
©
(6.8)
where a is age, the expected survival S∗e,a(t) was also matched for sex and calendar year, RSe,a(t)
is the stage-standardised relative survival, and RSe,a(t) is the stage-standardised relative sur-
vival using one of the alternative methods A, B, or C.
Stage-standardised LEL was used in the following way to estimate the total gain in life
years:
Total gain in life years =
2∑
e=1
99∑
a=21
Ne,a · (LELa,e − LELa,e) (6.9)
where LELa,e is the stage standardised LEL for age, a, and education group, e, and LELa,e is the
alternative LEL using either method A, B, or C. Note that gain in life years, in comparison to the
total gain in life years, were calculated as LELa,e − LELa,e and presented by age and education
group.
Confidence intervals for estimates
It is common to combine uncertainty of estimates using Rubin’s Rules when performing MI.
Current literature advises to combine estimates using Rubin’s Rules on the scale in which it was
modelled. For example, if we were interested in estimating survival but did this by modelling
the log hazard function, we would combine the imputation-specific estimates on the log hazard
scale and then translate this back to the survival scale [107]. To our knowledge there is no
advice on how to combine standardised estimates such as those used in this study. Consequently,
we instead used a bootstrapping method in the aim of combining the uncertainty involved in
the standardised estimates and the MI. The bootstrap was implemented in the following way:
1. Impute missing stage and education group 30 times using the MI methods previously
described.
2. Create one data set containing 30 variables for both stage and education group which
correspond to the 30 imputed values calculated from the MI.
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3. Bootstrap this dataset by drawing samples with replacement.
4. For each bootstrapped sample, loop over the 30 imputed variables and estimate each
standardised measure of interest using the imputed variables separately. Average the 30
estimates of interest.
5. Save each of these averaged estimates of interest from each of the bootstrapped samples.
6. Repeat the bootstrapping 100 times. Use the 100 averaged estimates and the normal
approximation method to estimate the confidence intervals.
6.4.3 Main results
Results indicated that on the population level, a gain of approximately 573 life years could be
obtained for a typical calendar year if the stage-distribution in all education groups was the
same as the high education group. When equating the stage-specific relative survival between
education groups, it was estimated that approximately 692 life years could be gained in a typical
calendar year. We estimated that approximately 50 deaths could be postponed five-years after
diagnosis during a typical calendar year if it was possible to remove both stage-distribution and
stage-specific relative survival differences between education groups. Approximately 25 deaths
could be postponed five years beyond diagnosis if it was possible to only remove the stage-
distribution differences and approximately 27 deaths could be postponed five years beyond
diagnosis if differences in stage-specific relative survival could be removed.
6.4.4 Additional results: proportion of expected life lost
In addition to the results presented in the paper, we also calculated the proportion of expected
life lost (PELL); see Table 6.5. The estimates of PELL predicted from models using the imputed
data set indicate that younger patients lose a larger proportion of their remaining life years
than older patients. For example a woman diagnosed with breast cancer at age 45 in the low
education group is predicted to lose 25% of their remaining life whereas a similar woman
diagnosed at age 75 would lose approximately 15% of their remaining life years due to their
diagnosis of breast cancer. The PELL results also indicate that patients in the low education
groups generally lose more than those in the medium or high education groups. We see that
larger benefits, i.e. smaller proportions, are seen when considering method C and removing all
differences in stage-distribution and stage-specific breast cancer survival between education
groups than just removing one of the two as in methods A and B.
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Proportion of life years lost
Age Education Original Method A Method B Method C
Low 0.252 0.222 0.231 0.202
Medium 0.238 0.228 0.217 0.20745
High 0.213 - - -
Low 0.181 0.158 0.164 0.143
Medium 0.168 0.154 0.160 0.14755
High 0.152 - - -
Low 0.132 0.125 0.119 0.113
Medium 0.120 0.118 0.118 0.11665
High 0.120 - - -
Low 0.171 0.145 0.155 0.131
Medium 0.134 0.137 0.132 0.13575
High 0.139 - - -
Table 6.5: The proportion of life years lost due to breast cancer for patients diagnosed in three regions of
Sweden between 2008 and 2012. ‘Original’ refers to predictions from models using imputed datasets but
without applying methods A-C. Method A refers to predictions where differences in stage distribution
between education groups are removed, Method B refers to estimates when removing differences in
stage-specific relative survival between education groups, and Method C estimates when removing both
differences in stage-distribution and stage-specific relative survival.
6.4.5 Sensitivity analyses
MI of missing stage resulted in an average stage distribution of 45.3%, 37.9%, 13.6% and 3.3%
of individuals being diagnosed with breast cancer at stage I, II, III and IV, respectively. We
performed sensitivity analyses to determine the conclusions that could have been drawn had
we chosen to perform a complete case analysis; results are shown when applying method A in
Table 6.6.
Larger differences in the life years lost between the MI and complete case analysis are seen
in the younger and older patients. The complete case analysis estimated a larger number life
years lost in the younger patients, and a smaller number of life years lost in the older patients
in comparison to the imputed analysis. The largest difference of approximately half a year was
seen for those aged 45 years. At the same time the gain in life years were largely unchanged
between the imputed and complete case analyses. This indicates that it makes little difference
whether a complete case analysis or MI is undertaken when altering the stage-distribution
using method A. The difference in the life years lost between the two analyses stem from
the differences in the population. These differences are consistent between the LEL and LEL
when applying method A, resulting in a similar gain in life years for the MI and complete case
analyses.
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Age Education
Life years lost (95% CI) Gain in life years (95% CI)
MI CC MI CC
8.68 9.13 1.21 1.22
Low
(7.27, 10.09) (7.60, 10.66) (1.13, 1.30) (1.12, 1.32)
9.27 9.83 0.42 0.41
45
Medium
(8.34, 10.21) (8.87, 10.80) (0.38, 0.46) (0.35, 0.47)
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Low
4.75 4.84 0.67 0.64
(4.18, 5.32) (425, 5.43) (0.64, 0.71) (0.60, 0.68)
Medium
4.83 5.05 0.44 0.45
(4.35, 5.31) (4.56, 5.54) (0.40, 0.47) (0.41, 0.49)
2.66 2.53 0.15 0.11
Low
(2.38, 2.93) (2.26, 2.80) (0.14, 0.17) (0.10, 0.12)
2.64 2.61 0.04 0.02
65
Medium
(2.40, 2.89) (2.33, 2.89) (0.03, 0.05) (0.01, 0.03)
75
Low
1.93 1.74 0.35 0.31
(1.77, 2.08) (1.60, 1.88) (0.34, 0.37) (0.29, 0.33)
Medium
1.94 1.79 -0.04 -0.06
(1.78, 2.10) (1.62, 1.97) (-0.06, -0.03) (-0.07, -0.05)
Table 6.6: LEL and gain in life years for breast cancer patients in Sweden when removing differences
in stage-distribution between education groups; MI versus complete case (CC)
6.4.6 Discussion
It is important to consider what effects we attempt to capture when quantifying differences be-
tween education groups in the described ways. Screening attendance may differ by educational
achievement which could contribute to the differences between education groups in stage at
diagnosis. Health awareness and subsequent healthcare-seeking behaviour, which differs over
SES groups, could have a similar effect. Differences in stage-specific survival could be explained
by lifestyle differences, access to healthcare and even treatment differences. We can really only
speculate which factors contribute to these differences and the potential interventions that
could be implemented to improve survival. It is practically impossible to remove all of these
differences with one intervention, but these results illustrate potential gains. Further work and
resources would be required to quantify why these differences occur, but understanding the
magnitude of these differences as shown in this study provide information to help prioritise
further research and potential interventions.
For this application we found that MI did not make a large difference in terms of conclusions
drawn. Nevertheless, imputation of stage can be highly important since missing stage informa-
tion is often considered not missing completely at random. Missing stage is more commonly
seen in older patients and patients with more advanced stage tumours since investigation of
such tumours is often deemed unnecessary since such patients are likely to receive palliative
treatment [108]. Moreover, inclusion of all individuals is highly important when wishing to
calculating values on a population level such as the total life years lost or the total gain in life
years.
The combination of estimating standardised measures and MI was methodologically com-
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plex; it was not clear how to undertake such a project. Regularly, Rubin’s Rules could be used
to estimate uncertainty in estimates calculated using MI, however, combining using Rubin’s
Rules was not an approach we considered here due to the standardisation. We instead used
a bootstrap approach which was 1) specific to this application, and 2) computationally inten-
sive. For these reasons, it would be useful to investigate generalised approaches for estimating
uncertainty in standardised measures estimated using imputed data.
The results presented would have been more useful if we had access to data from all regions
of Sweden, since we were truly interested in the effects for the whole country. We did present
estimates of the total life years lost and postponable deaths for the whole of Sweden, but in
order to do this we assumed that the study population represented Sweden in terms of expected
survival, relative survival, covariate effects and the stage distribution over education groups.
Under these assumptions we estimated that 1,340 life years could be saved for one calendar
year if stage-distributions could be equated over education groups (method A), and 2,878 life
years if stage-distributions and stage-specific relative survival could be equated across education
groups (method C). Although these assumptions are quite strong, and we suggest that readers
do not overinterpret these results, there are few reasons to believe that estimating over the
whole of Sweden would lead to dramatic changes to these estimates. It would, however, be
interesting to see how these assumptions affect the estimates if the data were available.
6.4.7 Conclusion
This study illustrates an alternative way to apply the LEL in quantifying survival of cancer
patients. We use counter-factual situations to quantify the impact a characteristic has on the
remaining life expectancy, the life years lost and the postponable deaths for a whole population.
Such estimates quantify the potential gains interventions could bring if implemented. In addi-
tion to gaining a better understanding of the impact of a factor on prognosis, this sort of analysis
could be used in a more practical sense to help determine what healthcare interventions are
worth investing in. We conclude that removing differences in both the stage distribution at
diagnosis of breast cancer and the stage-specific relative survival between education groups
could postpone approximately 50 deaths five years beyond diagnosis per year in three regions
of Sweden. On a national level, an estimated 117 deaths could be postponed five years beyond
diagnosis per year.
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Study I, whose results apply even outside of the population-based cancer studies field, showed
that non-proportional FPMs can be used to estimate survival, hazard rates and HRs with low
levels of bias when the selection of the degrees of freedom are guided by the AIC and BIC.
Users should perform relevant sensitivity analyses and consider that model mis-specification
can affect predicted hazard rates and ratios more than survival proportions.
Studies II and IV illustrated how the LEL can provide a further understanding of cancer
patient survival and works as a complement to the relative survival measure. Our application to
CML in Study II showed how the LEL can be used to assess the impact treatment improvements
can have on the life expectancy over time. We concluded that CML patients can now expect to
live almost as long as CML-free individuals.
The LEL can also be used to address questions about the potential population impact of
risk factors such as education. In Study IV we estimated LEL and postponable deaths in breast
cancer patients and determined the effect of differences between education groups. Such results
can help guide decisions on interventions aimed to remove survival differences between patient
groups.
We concluded from Study III that information from a random sample of the general popula-
tion can be utilised to estimate adjusted expected mortality rates using both Poisson models and
FPMs. This work offers the opportunity for quantification of survival measures by non-standard
factors which is an essential next step to understand remaining differences in survival between
patients.
Overall, each of the studies address and add to slightly different aspects of methodology
and understanding of survival of cancer patients in the population-based cancer studies field.
The work in these areas can always be developed further; here are some thoughts on extensions
and applications of the methods and results shown in this thesis.
Previous work has shown that extrapolation of relative survival is accurate in patients over
50 years of age, but there has been no assessment of the extrapolation for patients younger
than this age. The LEL is a highly useful measure due to its interpretation in terms of life
expectancy, and although life expectancy is of interest to everyone regardless of age, the im-
pact of a cancer diagnosis for younger patients is much larger since they have a much longer
remaining life expectancy and thus much more potential life to lose. This makes this measure
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particularly relevant for younger patients. The problems with extrapolation in these younger
patients include 1) extrapolation of relative survival in order to estimate LEL will be longer,
and 2) for many cancers, diagnoses in younger patients is less common, thus there are fewer
cases and increased uncertainty in any extrapolation. Work in this area would be of interest to
ensure that LEL can be accurately estimated for younger patients, or to determine when LEL
should not be estimated due to problems with extrapolation.
Similarly, applications of the LEL to other cancers is highly useful for the several reasons.
The LEL provides an alternative aspect of cancer survival in comparison to the common practice
of estimating and presenting relative survival. LEL can also be a helpful tool in understander-
standing what a diagnosis of cancer means for patients’ future life. Cancer registries commonly
report relative survival estimates; presenting such estimates is essential when comparing dif-
ferent subgroups and populations. Nevertheless, the inclusion of ‘real-world’ estimates, such as
total life years lost, in reports from cancer registries may be advantageous to understand the
burden cancer has on a population. Inclusion of such measures in reports from cancer registries
or other public reports or databases such as the NORDCAN project [19] is extremely important
in an age where the internet offers everyone access to information on cancer statistics. Patients
are using information published online to try to understand their diagnosis of cancer and the
likely impact it will have [109]. Presenting more easily understood measures such as the LEL
means they are more likely to intepret survival accurately.
Online tools are becoming more popular and have been implemented to illustrate particular
methodology via interactive graphs [110], and to help aid the understanding of cancer survival
statistics [111]. Such online tools could be developed to enhance understanding of both FPMs
and LEL estimates. Illustrating how changes in the degrees of freedom in FPMs alter commonly
used predictions could be useful for users to understand what model specifications mean and
where biases may occur. Online tools could also be useful to help understand the impact of
certain modelling assumptions when estimating LEL.
Study III implemented methods to smooth expected mortality rates. It is interesting to con-
sider the effects of smoothing expected mortality rates on measures such as relative survival
and whether such smoothing is actually needed. Approaches for smoothing rates in abridged
life tables seem sensible [65], but it is not clear how small the time intervals need to be before
smoothing is unnecessary. It may be interesting to investigate the implications of either assum-
ing expected rates are constant within specific time intervals versus the implications of making
modelling assumptions.
Related to this, the expected mortality rates are commonly assumed to carry no uncertainty
since they are obtained from a whole nation. One could alternatively follow the theory that
observed population mortality rates are taken from some underlying random process. Previous
research showed that accounting for this uncertainty does not significantly affect model-based
relative survival estimates [102]. However, when estimating LEL expected mortality rates are
used 1) to estimate relative survival, 2) to transform the relative survival back to the observed
survival, and 3) in estimating the life expectancy that patients would be expected to experience
had they not been diseased. Ignoring uncertainty in all three parts of estimating the LEL may
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have a larger impact and it would be interesting to assess whether this is true.
In the same manner, when modelling excess mortality using FPMs and estimating LEL, we
make one of two assumptions about the future expected mortality. We either 1) assume that
future expected rates are the same as the most recently recorded year, or 2) use predictions esti-
mated by demographers; in our applications predictions were obtained from Statistics Sweden.
It is always problematic when trying to predict the future, and although we have performed
some sensitivity analyses regarding these two assumptions in our specific applied studies, it
may be useful to do more extensive work into the differences that these two assumptions can
make and if one is preferable.
The MI in Study IV was undertaken using advice from Falcaro et al. on imputation using
relative survival. However, other methods for imputation in relative survival seem to be rather
limited. For example, if cause of death information is available, it could be useful to utilise
this information. If we knew that an individual died of cancer a short time after diagnosis of
that cancer, it seems more likely that they had a more advanced stage cancer at diagnosis. It
would be interesting to perform a simulation study using such information to assess whether
cause of death improves imputated data. It would also be useful to extend and generalise the
methodology used to calculate uncertainty when combining MI with standardised-measures
as performed in Study IV.
Further work related to FPMs in general could be to extend the use of FPMs on the log
hazard scale to modelling multiple timescales. It may be desirable to capture multiple timescales
in certain analyses, for example if we were interested in both time since diagnosis and attained
age, i.e., aging. Whilst working on Study I and Study III, and the strcs command in Stata, it
became clear that it was possible to model multiple timescales using FPMs on the log hazard
scale. The use of the numerical integration to calculate the log likelihood allows us to model
one timescale as a function of the other, since time progresses in the same way. This could be
interesting work since it removes the computationally intensive problem of time-splitting that
usually takes place when wishing to perform an analysis with multiple timescales.
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A.1 Hazard ratios estimated from flexible parametric models on
the log cumulative hazard scale
As described in section 5.1, coefficients estimated in FPMs can be interpreted as log HRs
provided there is at most one time-dependent effect. Consider the following FPM on the log
cumulative hazard scale with one time-dependent effect:
log[H(t)] = s0(α|γ) + β1 x + s1(α|δ1)x + β2z
⇒ H(t) = exp[s0(α|γ) + β1 x + s1(α|δ1)x + β2z],
where α= ln(t), x and z are indicator variables, and x has a time-dependent effect. If we set
x to be any value, i.e., x = x i , we can write the HR for z = 1 versus z = 0 as follows:
h(t|z = 1, x = x i)
h(t|z = 0, x = x i) =
d
d t
H(t|z = 1)
H(t|z = 0)
=
d
d t
exp[s0(α|γ) + β1 x i + s1(α|δ1)x i + β2]
exp[s0(α|γ) + β1 x i + s1(α|δ1)x i]
=
d
d t
exp[s0(α|γ)]exp(β1 x i)exp[s1(α|δ1)x i]exp(β2)
exp[s0(α|γ)]exp(β1 x i)exp[s1(α|δ1)x i]
=
d
d t
exp(β2)
= exp(β2)
Thus β2 can be interpreted as the log HR for z. When modelling on the log cumulative hazard
scale and including more than one time-dependent effect, problems arise. These are described
in the following section.
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A.2 Modelling multiple time-dependent effects using flexible
parametric models on the log cumulative hazard scale
Consider the following FPM with time-dependent effects of both x and z:
log[H(t)] = s0(α|γ) + β1 x + s1(α|δ1)x + β2z + s2(α|δ2)z
⇒ H(t) = exp[s0(α|γ) + β1 x + s1(α|δ1)x + β2z + s2(α|δ2)z].
Differentiating this in order to get the hazard function (note that for ease of reading RCS
functions are now denoted sk):
h(t) = (s′0 + s′1 x + s′2z)exp(s0 + β1 x + s1 x + β2z + s2z).
Now, if we want the HR for z = 1 versus z = 0, where x = x i , we get the following:
h(t|z = 1, x = x i)
h(t|z = 0, x = x i) =
(s′0 + s′1 x i + s′2)exp(s0 + β1 x i + s1 x i + β2 + s2)
(s′0 + s′1 x i)exp(s0 + β1 x i + s1 x i)
=
(s′0 + s′1 x i + s′2)exp(s0)exp(β1 x i)exp(s1 x i)exp(β2)exp(s2)
(s′0 + s′1 x i)exp(s0)exp(β1 x i)exp(s1 x i)
=
(s′0 + s′1 x i + s′2)exp(β2)exp(s2)
s′0 + s′1 x i
The HR for z is still dependent on the differentiated spline term for x , thus illustrating
the problem when modelling multiple time-dependent effects using FPMs on the log cumu-
lative scale. It should be noted that modelling with multiple time-dependent effects on the
log cumulative hazard scale is only a large problem when one is interested in reporting HRs.
This was not a problem for the studies presented in this thesis as focus was on individual level
predictions, not on HRs.
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